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A	  RARE	  VIEW	  OF	  CODING	  MUTATIONS	  AND	  PLASMA	  LIPID	  LEVELS.	  	  Aniruddh	  P.	  Patel,	  Sekar	  Kathiresan.	  	  Center	  for	  Human	  Genetics	  Research,	  Massachusetts	  General	  Hospital,	  Harvard	  Medical	  School,	  Boston,	  MA	  and	  Program	  in	  Medical	  and	  Population	  Genetics,	  the	  Broad	  Institute	  of	  Harvard	  and	  MIT,	  Cambridge,	  MA	  (Sponsored	  by	  Richard	  P.	  Lifton,	  Department	  of	  Genetics,	  Yale	  University	  School	  of	  Medicine,	  New	  Haven,	  CT).	  	  	   Plasma	  low-­‐density	  lipoprotein	  cholesterol	  (LDL-­‐C),	  high-­‐density	  lipoprotein	  cholesterol	  (HDL-­‐C),	  and	  triglycerides	  (TG)	  are	  quantitative,	  heritable	  risk	  factors	  for	  coronary	  heart	  disease.	  	  Genome-­‐wide	  association	  screens	  (GWAS)	  of	  common	  DNA	  sequence	  variants	  have	  identified	  many	  loci	  associated	  with	  plasma	  lipid	  levels.	  	  Targeted	  re-­‐sequencing	  of	  exons	  has	  been	  proposed	  as	  a	  strategy	  to	  pinpoint	  causal	  variants	  and	  genes	  based	  in	  GWAS	  loci.	  	  Additionally,	  genotyping	  of	  rare	  and	  low	  frequency	  variants	  in	  large	  cohorts	  using	  an	  exome	  array	  has	  been	  proposed	  as	  a	  method	  to	  assess	  the	  contribution	  of	  rare	  variation	  to	  plasma	  lipid	  levels	  at	  the	  population	  level.	  We	  tested	  the	  hypothesis	  that	  each	  genomic	  region	  identified	  with	  a	  significant	  HDL-­‐C	  level	  association	  by	  GWA	  studies	  contains	  at	  least	  one	  gene	  causal	  for	  HDL-­‐C	  metabolism.	  We	  performed	  solution-­‐based	  hybrid	  selection	  of	  4,118	  exons	  at	  407	  genes	  within	  47	  loci	  associated	  with	  HDL-­‐C	  and	  subsequently	  sequenced	  individuals	  drawn	  from	  the	  extremes	  of	  the	  HDL-­‐C	  distribution	  (high	  HDL-­‐C,	  n=385,	  mean=102	  mg/dl	  or	  low	  HDL-­‐C,	  n=334,	  mean=32	  mg/dl)	  using	  next-­‐generation	  sequencing	  technology.	  We	  tested	  whether	  rare	  coding	  sequence	  variants,	  individually	  or	  aggregated	  within	  a	  gene,	  were	  associated	  with	  HDL-­‐C.	  To	  replicate	  findings,	  we	  performed	  follow-­‐up	  genotyping	  using	  the	  Exome	  Array	  (Illumina	  HumanExome	  BeadChip)	  in	  independent	  participants	  with	  extremely	  high	  
	  
HDL-­‐C	  (n=514,	  mean=98	  mg/dl)	  or	  low	  HDL-­‐C	  (n=580,	  mean=32	  mg/dl).	  Through	  sequencing,	  we	  identified	  8,138	  rare	  (minor	  allele	  frequency	  <	  5%)	  missense,	  nonsense,	  or	  splice	  site	  variants.	  	  Across	  discovery	  sequencing	  and	  replication	  genotyping,	  we	  found	  3	  variants	  to	  be	  significantly	  associated	  with	  HDL-­‐C.	  	  Of	  these,	  none	  were	  novel.	  In	  gene-­‐level	  association	  analyses	  where	  rare	  variants	  within	  each	  gene	  are	  collapsed,	  only	  the	  CETP	  gene	  was	  associated	  with	  plasma	  HDL-­‐C	  (P=2.0	  x	  10-­‐6).	  	  After	  sequencing	  genes	  from	  GWAS	  loci	  in	  participants	  with	  extremely	  high	  or	  low	  HDL-­‐C,	  we	  did	  not	  identify	  any	  new	  rare	  coding	  sequence	  variants	  with	  a	  strong	  effect	  on	  HDL-­‐C.	  These	  results	  provide	  insight	  regarding	  the	  design	  of	  similar	  sequencing	  studies	  for	  cardiovascular	  traits	  with	  respect	  to	  sample	  size,	  follow-­‐up,	  and	  analysis	  methodology.	  
We	  then	  tested	  the	  hypothesis	  that	  rare	  coding	  and	  splice-­‐site	  mutations	  contribute	  to	  inter-­‐individual	  variability	  in	  plasma	  lipid	  concentrations	  in	  the	  population.	  We	  contributed	  to	  the	  design	  of	  a	  new,	  rare-­‐variant	  genotyping	  array	  based	  on	  the	  sequences	  of	  the	  protein-­‐coding	  regions	  of	  ~18,500	  genes	  (“the	  exome”)	  in	  >12,000	  individuals.	  	  This	  genotyping	  array	  (“the	  Exome	  Chip”)	  includes	  approximately	  250,000	  non-­‐synonymous	  and	  splice-­‐site	  mutations	  and	  is	  estimated	  to	  capture	  nearly	  all	  such	  variation	  with	  a	  >1:1000	  allele	  frequency	  in	  the	  European	  population.	  	  We	  obtained	  Exome	  Chip	  genotype	  data	  in	  >130,000	  individuals	  from	  58	  studies.	  	  Within	  each	  study,	  we	  tested	  the	  association	  of	  plasma	  lipids	  with	  individual	  rare	  variants.	  To	  combine	  statistical	  evidence	  across	  studies,	  we	  performed	  meta-­‐analysis.	  	  Top	  results	  for	  each	  trait	  replicated	  established	  associations	  in	  the	  genes	  APOE,	  CETP,	  and	  APOA5	  for	  LDL-­‐C,	  HDL-­‐C,	  and	  TG,	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   1	  
INTRODUCTION	  Cardiovascular	  disease	  (CVD)	  is	  the	  leading	  cause	  of	  death	  in	  the	  United	  States	  and	  in	  the	  world.1,2	  	  In	  addition	  to	  being	  the	  cause	  of	  death	  for	  almost	  600,000	  individuals	  in	  the	  United	  States	  each	  year,	  CVD	  accounts	  for	  much	  of	  the	  nation’s	  morbidity	  and	  health	  care	  system	  expenditure.	  	  In	  the	  US,	  11.5%	  of	  non-­‐institutionalized	  adults	  have	  been	  diagnosed	  with	  heart	  disease,	  and	  it	  is	  the	  primary	  diagnosis	  for	  over	  12.4	  million	  annual	  physician	  office	  visits	  and	  over	  3.7	  million	  hospital	  discharges,	  with	  the	  average	  length	  of	  inpatient	  stay	  being	  4.6	  days.	  	  Much	  of	  the	  mortality	  and	  morbidity	  from	  CVD	  stems	  from	  ischemic	  coronary	  heart	  disease	  (CHD),	  which	  includes	  angina	  pectoris,	  myocardial	  infarction,	  silent	  myocardial	  ischemia,	  and	  mortality	  resulting	  from	  coronary	  heart	  disease.3	  	  A	  deeper	  understanding	  of	  the	  causes	  of	  CHD	  will	  help	  guide	  prevention	  and	  treatment	  measures	  to	  decrease	  its	  burden	  of	  morbidty	  and	  mortality.	  	  
Risk	  Factors	  for	  Coronary	  Heart	  Disease	  The	  Framingham	  Heart	  Study	  first	  identified	  common	  risk	  factors	  contributing	  to	  CHD	  after	  following	  the	  development	  of	  disease	  in	  over	  10,000	  individuals	  across	  two	  generations	  through	  their	  lifetimes.	  	  In	  the	  1960's,	  the	  Study	  linked	  cigarette	  smoking,	  elevated	  cholesterol	  level,	  hypertension,	  electrocardiogram	  abnormalities,	  obesity,	  and	  physical	  inactivity	  with	  increased	  risk	  of	  heart	  disease.4	  	  In	  the	  1970's	  the	  Study	  reported	  heart	  disease	  associations	  with	  diabetes,	  menopause,	  and	  psychosocial	  factors.	  
	   2	  
These	  risk	  factors	  were	  incorporated	  into	  the	  calculation	  of	  a	  Framingham	  Risk	  score	  adjusted	  for	  sex	  and	  age,	  which	  has	  been	  used	  by	  physicians	  to	  predict	  CHD	  risk	  in	  patients	  without	  disease.5	  	  Using	  the	  Framingham	  data,	  the	  lifetime	  risk	  of	  developing	  CHD	  calculated	  at	  age	  40	  was	  one	  in	  two	  for	  men	  and	  one	  in	  three	  for	  women	  in	  the	  US,	  with	  the	  risk	  decreasing	  to	  one	  in	  three	  for	  men	  and	  one	  in	  four	  for	  women	  when	  calculated	  at	  70	  years.6	  A	  recent	  meta-­‐analysis	  of	  over	  250,000	  individuals	  confirmed	  that	  optimization	  of	  the	  burden	  of	  modifiable	  risk	  factors	  such	  as	  total	  cholesterol	  level,	  blood	  pressure,	  smoking,	  and	  diabetes	  resulted	  in	  a	  significant	  decrease	  in	  the	  lifetime	  risk	  of	  developing	  cardiovascular	  disease.7	  	  	  Of	  the	  largely	  lifestyle	  modifiable	  risk	  factors,	  diabetes,	  hypertension,	  and	  cholesterol	  levels	  are	  complex	  traits	  with	  a	  significant	  unmodifiable	  genetic	  component	  predisposing	  individuals	  to	  disease.	  	  In	  the	  past	  few	  decades,	  hundreds	  of	  genes	  and	  loci	  have	  been	  associated	  with	  these	  complex	  traits.	  	  Linkage	  and	  sequencing	  studies	  have	  identified	  numerous	  genes	  with	  rare	  variants	  involved	  in	  the	  pathogenesis	  of	  type	  2	  diabetes,8-­‐16	  and	  a	  series	  of	  GWA	  studies	  have	  reported	  common	  variants	  influencing	  risk	  of	  developing	  the	  disease.17-­‐22	  Consortia	  have	  also	  reported	  common	  variants	  with	  significant	  associations	  with	  hypertension.23-­‐25	  	  Our	  group	  (laboratory	  of	  R.P.	  Lifton)	  has	  investigated	  and	  reported	  a	  number	  of	  genes	  involved	  in	  the	  pathogenesis	  of	  Mendelian	  hypertension	  syndromes.26-­‐35	  	  Furthermore,	  our	  group	  (laboratory	  of	  S.	  Kathiresan)	  has	  reported	  several	  genes	  and	  variants	  contributing	  to	  variation	  of	  plasma	  lipid	  levels	  in	  families	  and	  in	  the	  population.	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Role	  of	  Plasma	  Lipids	  in	  Coronary	  Heart	  Disease	  Human	  plasma	  contains	  five	  major	  lipid	  subgroups	  differentiated	  by	  their	  density	  and	  apoprotein	  content:	  high	  density	  lipoprotein	  (HDL),	  low	  density	  lipoprotein	  (LDL),	  intermediate	  density	  lipoprotein	  (IDL),	  very	  low	  density	  lipoprotein	  (VLDL),	  and	  chylomicrons.	  	  Naturally	  hydrophobic	  plasma	  lipids	  are	  made	  soluble	  in	  plasma	  through	  encapsulation	  by	  lipoproteins	  that	  carry	  lipids	  to	  tissues	  to	  serve	  as	  fuel,	  structural	  components,	  and	  building	  blocks	  for	  steroid	  hormones	  and	  bile	  acids.	  	  The	  lipoprotein	  particle	  is	  composed	  of	  a	  shell	  of	  phospholipids,	  cholesterol,	  and	  apoproteins	  filled	  with	  triglycerides	  and	  cholesterol	  esters.	  	  Lipoprotein	  particles	  are	  classified	  by	  their	  density	  and	  apoprotein	  content,	  with	  LDL	  carrying	  mostly	  cholesterol	  and	  VLDL	  and	  chylomicrons	  carrying	  mostly	  triglycerides	  (Figure	  1).	  	  Triglyceride	  measurements	  capture	  mainly	  chylomicrons	  and	  VLDL	  particles,	  LDL-­‐C	  measurements	  capture	  LDL	  particles,	  and	  HDL-­‐C	  measurements	  capture	  HDL	  particles.	  Total	  cholesterol,	  LDL-­‐C,	  HDL-­‐C,	  and	  triglyceride	  levels	  are	  lab	  tests	  commonly	  ordered	  as	  part	  of	  a	  lipid	  panel	  for	  the	  screening	  and	  monitoring	  of	  coronary	  heart	  disease.	  	  Total	  cholesterol	  and	  HDL-­‐C	  are	  measured	  using	  direct	  methods	  and	  are	  reliable	  regardless	  of	  whether	  the	  individual	  is	  fasting	  or	  not	  fasting.	  	  Triglyceride	  levels	  must	  be	  measured	  in	  the	  non-­‐fasting	  state	  for	  baseline	  uniformity.	  	  The	  LDL-­‐C	  level	  is	  calculated	  using	  the	  Friedewald	  equation	  where	  HDL-­‐C	  and	  triglyceride	  components	  are	  removed	  from	  the	  total	  cholesterol	  value:	  (LDL	  =	  TC	  –	  HDL	  –	  (TG/5)).36	  	  This	  method	  of	  obtaining	  LDL-­‐C	  is	  only	  reliable	  in	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individuals	  who	  are	  fasting	  and	  without	  other	  presentations	  of	  hypertriglyceridemia	  (TG>400	  mg/dl).	  	  
Figure	  1:	  Classification	  and	  Composition	  of	  Plasma	  Lipid	  Particles
	  Plasma	  lipid	  particles	  are	  classified	  based	  on	  their	  flotation	  density/ultracentrifugation.	  	  The	  physical	  properties,	  apolipoprotein	  content,	  and	  plasma	  lipid	  composition	  of	  the	  different	  particles	  are	  shown.	  	  Figure	  from	  Saland	  and	  Ginsberg,	  2007.37	  	  Lifestyle	  factors	  play	  a	  large	  role	  in	  determining	  plasma	  lipid	  levels.	  	  A	  diet	  high	  in	  cholesterol	  and	  saturated	  fats	  from	  animal	  products	  or	  hydrogenated	  oils	  raises	  plasma	  cholesterol	  and	  triglyceride	  levels,	  but	  diets	  with	  higher	  proportions	  of	  polyunsaturated	  fats	  lower	  total	  cholesterol	  levels.	  	  Physical	  activity	  and	  moderate	  amounts	  of	  meat	  and	  ethanol	  intake	  help	  raise	  HDL-­‐C	  levels,	  but	  inactivity,	  smoking,	  and	  obesity	  are	  associated	  with	  decreased	  HDL-­‐C	  levels.38	  Dietary	  cholesterol	  and	  fatty	  acids	  are	  absorbed	  through	  the	  intestinal	  epithelium,	  where	  fatty	  acids	  are	  combined	  with	  glycerol	  to	  form	  triglycerides	  and	  cholesterol	  is	  esterified.	  	  These	  lipids	  are	  packaged	  into	  chylomicrons	  and	  transported	  to	  the	  tissues	  via	  the	  circulation.	  	  The	  liver	  also	  synthesizes	  triglycerides	  and	  cholesterol	  esters	  and	  assembles	  them	  into	  VLDL	  particles	  for	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secretion	  into	  the	  blood	  stream	  and	  delivery	  to	  the	  tissues.	  	  As	  VLDL	  particles	  are	  depleted	  of	  their	  triglyceride	  content,	  their	  density	  increases.	  	  These	  remnants	  are	  then	  cleared	  by	  the	  liver	  along	  with	  the	  chylomicron	  remnants,	  or	  they	  are	  remodeled	  into	  LDL	  particles.39	  	  Lipid	  metabolism	  plays	  a	  key	  role	  in	  the	  pathogenesis	  of	  CHD	  and	  atheroma	  formation	  and	  modification.	  (Figure	  2)	  	  
Figure	  2:	  	  Overview	  of	  Lipid	  Metabolism	  and	  Role	  in	  Atherosclerosis
	  Chylomicron	  particles	  generated	  in	  the	  gastrointestinal	  tract	  and	  VLDL	  and	  LDL	  particles	  generated	  in	  the	  liver	  contribute	  to	  atheroma	  formation	  in	  the	  arterial	  wall.	  	  HDL	  particles	  help	  transport	  cholesterol	  from	  the	  tissues	  to	  the	  liver.	  	  Figure	  adapted	  from	  Badimón	  and	  Ibáñez,	  2010.40	  	  Low-­‐density	  lipoprotein	  cholesterol	  is	  primarily	  responsible	  for	  atherosclerosis.	  	  LDL-­‐C	  is	  first	  transported	  into	  the	  artery	  wall	  though	  a	  concentration-­‐dependent	  process	  which	  is	  accelerated	  in	  the	  setting	  of	  endothelial	  injury	  and	  hypercholesterolemia.	  	  The	  LDL-­‐C	  retained	  in	  the	  vessel	  intima	  is	  then	  oxidized	  by	  free	  radical	  species	  generated	  by	  nearby	  endothelial	  cells	  and	  macrophages.	  	  Local	  macrophages	  phagocytize	  the	  oxidized	  LDL-­‐C	  through	  the	  scavenger	  receptor	  and	  transform	  into	  foam	  cells	  storing	  massive	  amounts	  of	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oxidized	  lipids.	  	  Oxidized	  LDL-­‐C	  stimulates	  an	  inflammatory	  response	  through	  the	  release	  of	  cytokines	  and	  chemokines	  by	  local	  cells	  that	  leads	  to	  monocyte	  and	  lymphocyte	  recruitment	  and	  vascular	  smooth	  muscle	  cell	  proliferation.	  	  This	  results	  in	  the	  development	  of	  a	  raised	  atheromatous	  plaque	  with	  a	  lipid	  core	  and	  fibrous	  cap	  which	  can	  obstruct	  coronary	  blood	  flow,	  weaken	  the	  vessel	  wall	  leading	  to	  aneurysm	  formation,	  and	  rupture	  to	  lead	  to	  thrombosis	  and	  myocardial	  infarction.38	  In	  contrast	  to	  LDL-­‐C,	  HDL-­‐C	  has	  been	  shown	  to	  have	  a	  cardioprotective	  function.	  	  HDL	  is	  the	  primary	  mediator	  of	  reverse	  cholesterol	  transport,	  which	  removes	  cholesterol	  from	  peripheral	  tissues	  and	  brings	  it	  to	  the	  liver	  for	  biliary	  excretion.	  Furthermore,	  HDL	  has	  a	  number	  of	  non-­‐cholesterol-­‐mediated	  functions	  that	  may	  contribute	  to	  endothelial	  integrity	  and	  atheroprotection,	  such	  as	  anti-­‐inflammatory	  effects,	  anti-­‐oxidant	  effects,	  and	  anti-­‐thrombotic	  effects.41	  The	  role	  of	  triglyceride	  levels	  in	  coronary	  heart	  disease	  remains	  unclear	  because	  hypertriglyceridemia	  usually	  occurs	  in	  the	  setting	  of	  low	  HDL	  levels	  and	  increased	  LDL	  levels.42	  	  VLDL	  triglyceride	  particles	  enriched	  in	  apolipoprotein	  E	  or	  B	  have	  been	  shown	  to	  increase	  cholesterol	  uptake	  and	  oxidation	  in	  atheromas.43	  	  Furthermore,	  hypertriglyceridemia	  is	  conducive	  to	  hypercoagulability	  due	  to	  increased	  blood	  viscosity.44	  Although	  the	  initial	  epidemiological	  studies	  have	  shown	  that	  plasma	  lipid	  levels	  have	  an	  association	  with	  coronary	  heart	  disease	  and	  functional	  studies	  have	  postulated	  the	  general	  role	  of	  lipids	  in	  metabolism,	  these	  studies	  alone	  cannot	  distinguish	  if	  lipids	  play	  a	  pathologically	  causal	  role	  or	  are	  just	  markers	  of	  underlying	  disease.	  	  The	  gold	  standard	  for	  assessing	  such	  causality	  is	  through	  large-­‐
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scale	  randomized	  trials.	  	  For	  LDL-­‐C,	  results	  from	  several,	  large,	  randomized	  controlled	  trials	  of	  statin	  medications	  that	  lower	  plasma	  LDL-­‐C	  levels	  and	  rates	  of	  myocardial	  infarction	  suggest	  that	  LDL-­‐C	  plays	  a	  causal	  role	  in	  coronary	  heart	  disease.45-­‐49	  	  Large	  randomized	  controlled	  trials	  using	  niacin	  and	  torcetrapib	  to	  raise	  HDL-­‐C	  levels	  did	  not	  result	  in	  a	  significant	  reduction	  in	  coronary	  heart	  disease,	  suggesting	  that	  HDL-­‐C	  does	  not	  play	  a	  causal	  role	  in	  the	  underlying	  pathophysiology.	  	  Randomized	  controlled	  trials	  using	  fish	  oils	  and	  fibrates	  to	  lower	  triglyceride	  levels	  had	  mixed	  results	  in	  altering	  the	  risk	  of	  coronary	  heart	  disease,	  and	  the	  causal	  role	  of	  triglycerides	  is	  difficult	  to	  interpret	  because	  the	  administered	  medications	  have	  significant	  effects	  on	  the	  other	  lipid	  fractions.50,51	  Analyzing	  lipid	  levels	  in	  the	  context	  inherited	  DNA	  variation	  may	  also	  be	  employed	  to	  distinguish	  causality	  of	  a	  biomarker	  using	  the	  theory	  of	  Mendelian	  randomization,	  which	  relies	  on	  the	  fact	  that	  genotypes	  are	  randomly	  assigned	  at	  meiosis	  and	  remain	  independent	  of	  non-­‐genetic	  confounders	  or	  other	  disease	  processes.52	  	  In	  this	  sense,	  the	  assignment	  of	  genotypes	  at	  birth	  is	  analogous	  to	  the	  randomized,	  double-­‐blinded	  administration	  of	  a	  medication	  in	  a	  clinical	  trial.	  	  Based	  on	  a	  representative	  set	  of	  significant	  SNPs	  tested	  using	  Mendelian	  randomization,	  our	  group	  recently	  reported	  evidence	  suggesting	  independent,	  causal	  roles	  of	  TG,	  in	  addition	  to	  LDL-­‐C,	  in	  the	  pathogenesis	  of	  CHD.53	  	  We	  also	  reported	  similar	  evidence	  suggesting	  that	  some	  common	  genetic	  mechanisms	  that	  raise	  HDL-­‐C	  do	  not	  contribute	  to	  CHD	  risk.54	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Genetics	  of	  Plasma	  Lipid	  Levels	  Many	  groups	  have	  determined	  that	  a	  large	  portion	  of	  the	  variation	  that	  we	  see	  in	  plasma	  lipid	  levels	  at	  the	  population	  level	  is	  heritable,	  or	  explained	  by	  inherited	  genetic	  differences.55	  	  Heritability	  estimates	  of	  lipid	  levels	  based	  on	  the	  Framingham	  data	  were	  calculated	  to	  be	  66%	  for	  LDL-­‐C,	  69%	  for	  HDL-­‐C,	  and	  58%	  for	  TG.56	  	  The	  systematic	  study	  of	  these	  genetic	  differences	  can	  help	  reveal	  causal	  biologic	  mechanisms	  of	  lipid	  metabolism.	  	  Studies	  of	  linkage	  analysis	  and	  candidate	  genes	  were	  first	  used	  to	  identify	  genes	  implicated	  in	  lipid	  metabolism.	  	  The	  development	  of	  DNA	  sequencing	  technologies	  has	  helped	  fine	  map	  larger	  and	  larger	  genetic	  regions	  in	  individuals	  to	  discover	  variants	  influencing	  plasma	  lipid	  levels.57	  	  Furthermore,	  the	  completion	  of	  the	  Human	  Genome	  Project	  and	  the	  International	  Haplotype	  Map	  Project	  has	  further	  expanded	  investigative	  possibilities	  by	  allowing	  genome-­‐wide	  screening	  of	  common	  variants	  to	  discover	  novel	  associations	  with	  plasma	  lipids.58,59	  These	  insights	  from	  genetics	  can	  be	  applied	  to	  the	  development	  novel	  therapeutics	  to	  treat	  at	  risk	  patients.60	  Plasma	  lipid	  levels	  are	  quantitative	  traits	  with	  complex	  inheritance	  patterns	  in	  which	  multiple	  genes	  and	  non-­‐genetic	  factors	  collude	  to	  influence	  the	  final	  phenotype.	  	  The	  genetic	  architecture	  underlying	  plasma	  lipids	  can	  be	  divided	  and	  examined	  by	  the	  minor	  allele	  frequency	  and	  effect	  sizes	  of	  significant	  variant	  associations	  (Figure	  3).	  	  Very	  rare	  variants	  are	  those	  with	  a	  frequency	  of	  less	  than	  0.1%,	  reflecting	  that	  fewer	  than	  1	  in	  1000	  people	  have	  the	  variant.	  	  These	  tend	  to	  have	  a	  larger	  effect	  on	  plasma	  lipid	  levels	  and	  may	  need	  to	  be	  grouped	  together	  to	  test	  their	  associations	  with	  lipid	  levels	  in	  aggregate.	  	  Low	  frequency	  variants	  are	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defined	  as	  having	  allele	  frequencies	  between	  0.1%	  and	  5%,	  or	  1:1000-­‐1:20	  in	  the	  population.	  	  Common	  variants	  are	  those	  with	  a	  frequency	  of	  greater	  than	  5%,	  or	  >1:20	  in	  the	  population,	  and	  they	  tend	  to	  have	  smaller	  effects	  on	  lipid	  levels.	  	  
Figure	  3:	  Genetic	  Architecture	  of	  Complex	  Traits	  
	  Variants	  are	  grouped	  as	  very	  rare	  (<1:1000),	  low	  frequency	  (1:1000-­‐1:20),	  and	  common	  (>1:20)	  based	  on	  allele	  frequency,	  which	  tends	  to	  be	  inversely	  correlated	  with	  magnitude	  of	  effect.	  Adapted	  from	  Kathiresan	  and	  Srivastava60	  	  Genome-­‐wide	  linkage	  mapping	  in	  families	  with	  extreme	  lipid	  phenotypes	  has	  identified	  over	  a	  dozen	  genes	  with	  very	  rare	  mutations	  responsible	  for	  Mendelian	  dyslipidemias.	  	  Linkage	  and	  DNA	  sequencing	  analyses	  were	  first	  used	  to	  identify	  a	  large	  deletion	  in	  the	  LDL	  receptor	  in	  a	  patient	  with	  familial	  hypercholesterolemia.61	  	  Further	  study	  of	  families	  with	  hypercholesterolemia	  with	  linkage	  analysis	  and	  sequencing	  led	  to	  the	  identification	  of	  PCSK9	  (inducer	  of	  LDL	  receptor	  degredation	  in	  liver)	  and	  APOB	  (an	  LDL	  receptor	  ligand	  for	  uptake	  in	  tissues)	  as	  having	  casual	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roles	  in	  dyslipidemias.62,63	  Other	  genes	  discovered	  through	  similar	  methods	  include	  
ARH	  (an	  adaptor	  protein	  for	  LDLR)	  in	  autosomal	  recessive	  hypercholesterolemia	  and	  ABCG5/ABCG8	  (ATP-­‐binding	  cassette	  transporters	  involved	  in	  biliary	  sterol	  excretion)	  in	  sitosterolemia.64,65	  	  Recently,	  our	  lab	  used	  exome	  sequencing	  to	  discover	  that	  rare	  mutations	  in	  ANGPTL3	  (an	  inhibitor	  of	  lipoprotein	  lipase	  and	  hepatic	  lipase)	  are	  responsible	  for	  combined	  hypolipidemia	  in	  a	  family	  with	  markedly	  low	  levels	  of	  LDL-­‐C,	  HDL-­‐C,	  and	  TG	  in	  their	  plasma.66	  	  Many	  of	  the	  genes	  implicated	  in	  Mendelian	  dyslipidemias	  are	  in	  the	  vicinity	  of	  common	  variant	  associations,	  some	  of	  which	  are	  targets	  of	  lipid	  lowering	  drugs.	  (Figure	  4).	  	  	  
Figure	  4:	  Overlap	  of	  Genetic	  Loci	  Causing	  Mendelian	  Dyslipidemias,	  Loci	  
Targeted	  by	  Lipid-­‐Lowering	  Drugs,	  and	  Loci	  Identified	  in	  GWAS
	  GWAS	  loci	  are	  named	  for	  a	  plausible	  candidate	  gene	  in	  the	  proximity	  of	  the	  variant	  with	  the	  top	  association.	  	  Many	  genes	  identified	  as	  causal	  in	  Mendelian	  dyslipidemias	  are	  near	  GWAS	  loci.	  	  Medications	  currently	  target	  several	  of	  these	  genes.	  	  Figure	  from	  Kathiresan	  and	  Srivastava,	  2012.60	  	  	  Genome-­‐wide	  association	  (GWA)	  studies	  have	  been	  used	  to	  identify	  common	  variants	  associated	  with	  the	  plasma	  lipid	  levels	  through	  the	  efficient	  genotyping	  of	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hundreds	  of	  thousands	  of	  common	  single	  nucleotide	  polymorphisms	  (SNPs)	  distributed	  throughout	  the	  genome.	  	  Significant	  associations	  detected	  through	  GWA	  studies	  implicate	  not	  just	  the	  variant	  with	  the	  strongest	  signal,	  but	  also	  several	  variants	  in	  the	  surrounding	  locus	  found	  to	  be	  in	  linkage	  disequilibrium	  with	  the	  index	  signal.	  	  Our	  lab	  has	  helped	  lead	  a	  concerted	  effort	  in	  using	  genome-­‐wide	  association	  (GWA)	  mapping	  in	  populations	  to	  define	  many	  new	  loci	  related	  to	  plasma	  lipids,	  with	  the	  most	  recent	  iteration	  cataloging	  common	  variants	  at	  157	  loci	  with	  genome-­‐wide	  significant	  associations.67-­‐71	  Furthermore,	  our	  group	  has	  reported	  that	  one	  of	  these	  common,	  noncoding	  GWAS-­‐implicated	  variants	  at	  the	  chromosome	  1p13	  locus	  is	  involved	  in	  a	  novel	  regulatory	  pathway	  where	  altered	  transcription	  factor	  binding	  leads	  to	  altered	  expression	  of	  SORT1	  (sortilin	  1,	  involved	  in	  pre-­‐secretory	  degradation	  of	  VLDL-­‐C)	  and	  altered	  risk	  for	  CHD.72	  Despite	  this	  progress	  in	  linkage	  analysis,	  sequencing	  technologies,	  and	  genotyping	  capabilities,	  the	  identified	  alleles	  with	  significant	  associations	  explain	  only	  a	  modest	  fraction	  of	  the	  overall	  variance	  in	  plasma	  lipid	  concentrations.	  	  Moreover	  the	  common	  variant	  associations	  identified	  by	  GWA	  studies	  only	  implicate	  a	  collection	  of	  variants	  in	  a	  general	  locus,	  and	  the	  true	  causes	  of	  the	  GWA	  signals	  are	  unknown.	  	  For	  loci	  mapped	  using	  GWAS,	  we	  need	  to	  move	  from	  locus	  to	  gene	  and	  pinpoint	  the	  specific	  causal	  gene	  and	  causal	  variant	  responsible	  for	  the	  association.	  	  Furthermore,	  although	  family	  studies	  aid	  in	  the	  investigation	  of	  Mendelian	  syndromes	  and	  GWA	  studies	  help	  uncover	  common	  variants	  with	  strong	  associations,	  low	  frequency	  variants	  with	  allele	  frequencies	  of	  1:1000-­‐1:20	  in	  population	  are	  difficult	  to	  discover	  with	  the	  methods	  mentioned	  so	  far.	  	  The	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contribution	  of	  rare	  and	  low	  frequency	  genetic	  variation	  at	  the	  population	  level	  is	  unknown.	  	  Within	  the	  bounds	  of	  the	  exome,	  we	  need	  to	  interrogate	  the	  significance	  of	  low	  frequency	  and	  rare	  variants	  in	  large	  cohorts	  to	  discover	  new	  genes	  implicated	  in	  lipid	  metabolism	  and	  coronary	  heart	  disease.	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STRUCTURE	  OF	  THESIS	  
	  
	   This	  thesis	  focuses	  on	  the	  role	  of	  rare	  variants	  and	  plasma	  lipid	  levels.	  	  Genetic	  architecture	  generally	  determines	  the	  method	  of	  investigation.	  	  Mendelian	  syndromes	  lend	  themselves	  to	  linkage	  and	  exome	  sequencing	  analysis	  in	  the	  context	  of	  pedigrees	  with	  well-­‐developed	  phenotypes.	  	  Common	  diseases	  and	  traits	  such	  as	  plasma	  lipid	  levels	  tend	  to	  have	  polygenic	  contributions,	  and	  the	  minor	  allele	  frequency	  range	  of	  interest	  determines	  method	  of	  inquiry	  (Figure	  5).	  
	  
Figure	  5:	  Investigative	  Genetic	  Method	  by	  Trait	  Type	  and	  Frequency	  Range	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Part	  I:	  	  Targeted	  Sequencing	  of	  GWAS	  Loci	  in	  Extremes	  of	  the	  High-­‐density	  
Lipoprotein	  Cholesterol	  Distribution	  
	  
BACKGROUND	  High-­‐density	  lipoprotein	  cholesterol	  (HDL-­‐C)	  is	  a	  highly	  heritable	  risk	  factor	  for	  coronary	  heart	  disease.4	  	  Genome-­‐wide	  association	  (GWA)	  studies	  have	  identified	  many	  new	  single	  nucleotide	  polymorphisms	  (SNP)	  related	  to	  HDL-­‐C	  in	  the	  population.17,67,68,70,71,73-­‐75	  	  Most	  associated	  SNPs	  are	  non-­‐coding	  (intergenic	  or	  intronic)	  and	  fall	  in	  regions	  of	  linkage	  disequilibrium	  extending	  tens	  of	  thousands	  of	  bases	  and	  containing	  many	  protein-­‐coding	  genes.	  	  Thus,	  a	  major	  challenge	  at	  each	  GWAS	  locus	  is	  to	  identify	  the	  culprit	  gene	  and	  variant	  responsible	  for	  the	  association	  signal.	  	  	   One	  approach	  to	  pinpoint	  causal	  genes	  and	  variants	  at	  GWAS	  loci	  is	  to	  perform	  fine	  mapping	  through	  targeted	  sequencing.	  	  Sequencing	  may	  identify	  a	  protein-­‐altering	  variant	  in	  a	  gene,	  which	  if	  associated	  with	  HDL-­‐C	  would	  suggest	  that	  the	  gene	  is	  influencing	  HDL-­‐C	  variation.	  	  The	  discovery	  of	  rare	  nonsense	  alleles	  that	  affect	  a	  trait	  may	  be	  particularly	  informative.	  	  Targeted	  sequencing	  of	  GWAS	  loci	  has	  been	  used	  to	  pinpoint	  independent	  rare	  variants	  and	  causal	  genes	  for	  diabetes	  mellitus,76	  fetal	  hemoglobin,77	  age-­‐related	  macular	  degeneration,78-­‐82	  and	  Crohn's	  disease.83	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HYPOTHESIS	  AND	  SPECIFIC	  AIMS	  	   We	  hypothesized	  that	  each	  genomic	  region	  identified	  with	  a	  significant	  HDL-­‐C	  level	  association	  by	  GWA	  studies	  contains	  at	  least	  one	  gene	  causal	  for	  HDL-­‐C	  metabolism.	  	  Our	  specific	  aims	  were	  as	  follows:	  	   1).	  Identified	  47	  GWAS	  loci	  for	  HDL-­‐C,	  targeted	  all	  exons	  at	  407	  genes	  within	  	  	   these	  genomic	  regions	  for	  sequencing,	  and	  sequenced	  targeted	  regions	  in	  	  	   individuals	  with	  extremely	  high	  or	  low	  HDL-­‐C.	  	   2).	  Attempted	  replication	  in	  an	  independent	  sample	  through	  array-­‐based	  	  	   genotyping.	  	  	  	   3).	  Assessed	  for	  novel,	  coding	  variants	  and	  genes	  with	  large	  effect	  in	  GWAS	  	  	   loci	  associated	  with	  HDL-­‐C	  to	  try	  to	  determine	  the	  functional	  HDL-­‐C	  gene	  at	  	  	   each	  locus.	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METHODS	  
Discovery	  Cohort	  Selection	  	  	  Individuals	  of	  European	  ancestry	  who	  had	  an	  abnormally	  high	  or	  low	  HDL-­‐C	  level	  (<35	  mg/dl	  for	  women	  and	  <28	  mg/dl	  for	  men	  or	  >	  100mg/dl	  for	  women	  and	  >80	  mg/dl	  men)	  were	  recruited	  at	  the	  University	  of	  Pennsylvania	  to	  participate	  in	  the	  study.	  	  Individuals	  with	  no	  history	  of	  liver	  disease	  or	  HIV	  and	  who	  were	  not	  pregnant,	  nursing,	  or	  taking	  hormone	  replacement	  therapy	  or	  niacin	  had	  ~40cc	  of	  blood	  drawn.	  	  Plasma	  lipid	  levels	  were	  measured,	  and	  whole	  genomic	  DNA	  was	  extracted	  from	  the	  blood	  of	  these	  individuals.	  	  Individuals	  with	  HDL-­‐C	  levels	  greater	  than	  the	  95th	  percentile	  were	  selected	  for	  targeted	  sequencing	  (n=389,	  mean	  HDL-­‐C	  =	  102	  mg/dl).	  	  Healthy	  age	  and	  sex	  matched	  controls	  with	  plasma	  HDL-­‐C	  levels	  <	  25th	  percentile	  were	  also	  sequenced	  (n=387,	  mean	  HDL=32mg/dl)	  (Table	  1).	  
	  
Targeted	  Sequencing	  We	  studied	  47	  loci	  previously	  mapped	  for	  HDL-­‐C	  (P	  <	  5	  x	  10-­‐8)	  in	  a	  genome-­‐wide	  association	  study	  (GWAS)	  meta-­‐analysis	  involving	  >100,000	  individuals	  by	  the	  Global	  Lipids	  Genetics	  Consortium.70,71	  For	  each	  locus,	  we	  selected	  all	  of	  the	  exons	  of	  genes	  within	  300	  kb	  from	  the	  lead	  GWAS	  SNP	  identified	  in	  that	  locus.	  	  This	  represented	  4,118	  exons	  at	  407	  genes.	  Solution-­‐based	  hybrid	  selection	  was	  used	  to	  select	  exons.84	  	  	  	   To	  amplify	  exons,	  target-­‐specific	  oligonucleotides	  170	  bases	  in	  length	  were	  designed	  to	  cover	  the	  entire	  coding	  sequence	  (hybrid	  selection	  bait	  size:	  262,873	  bases).	  	  These	  170-­‐mers	  were	  flanked	  on	  both	  sides	  with	  universal	  primer	  sequence	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to	  allow	  for	  PCR	  amplification.	  	  A	  T7	  promoter	  was	  added	  in	  a	  second	  round	  of	  PCR,	  and	  in	  vitro	  transcription	  in	  the	  presence	  of	  biotin-­‐UTP	  was	  performed	  to	  generate	  single-­‐stranded	  hybridization	  bait	  to	  capture	  targets	  of	  interest	  from	  the	  DNA	  sample.	  	  Genomic	  DNA	  from	  individuals	  was	  randomly	  sheared	  and	  ligated	  to	  Illumina	  sequencing	  adapters.	  	  The	  fragments	  of	  this	  sheared	  and	  ligated	  genomic	  DNA	  were	  PCR	  amplified	  for	  12	  cycles	  and	  hybridized	  with	  biotinylated	  RNA	  bait.	  	  The	  hybridized	  DNA	  was	  extracted	  and	  PCR	  amplified	  to	  generate	  36-­‐base	  sequencing	  reads	  off	  of	  the	  Illumina	  adaptor	  sequence	  at	  the	  ends	  of	  each	  fragment.	  	  	  	   Next	  generation	  sequencing	  reactions	  were	  performed	  using	  Illumina	  Genome	  Analyzers.	  Base	  pairs	  were	  called	  and	  sequencing	  reads	  were	  aligned	  to	  the	  human	  genome	  reference	  GRCh37	  (hg19).	  	  Sequencing	  metrics	  were	  calculated	  using	  the	  Picard	  data-­‐processing	  pipeline	  with	  an	  output	  of	  Binary	  Alignment	  Map	  (BAM)	  files.	  	  The	  Genome	  Analysis	  Toolkit	  suite	  was	  used	  to	  genotype	  all	  variant	  sites,	  calculate	  initial	  quality	  control	  metrics,	  and	  filter	  based	  on	  these	  values	  to	  result	  in	  an	  output	  of	  Variant	  Call	  Format	  (VCF)	  files,	  which	  were	  used	  for	  further	  quality	  control	  and	  analysis.85	  	  Variants	  were	  annotated	  using	  SnpEFF.86	  	  	  	  
Discovery	  Cohort	  Quality	  Control	  Samples	  that	  failed	  in	  any	  step	  of	  the	  solution	  hybrid	  selection	  component	  of	  the	  targeted	  sequencing	  process	  were	  excluded.	  	  Population	  clustering	  was	  assessed	  through	  multidimensional	  scaling	  using	  pruned	  common	  variants	  (>5%	  minor	  allele	  frequency)	  with	  high	  call	  rates	  and	  that	  were	  not	  in	  linkage	  disequilibrium.	  	  Outliers	  on	  a	  plot	  of	  the	  first	  two	  principal	  components	  generated	  from	  multidimensional	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scaling	  were	  excluded.	  	  Samples	  with	  high	  heterozygosity	  rates	  (number	  of	  heterozygote	  sites/number	  of	  variants	  per	  sample)	  were	  excluded	  as	  presumptively	  contaminated,	  and	  those	  with	  high	  singleton	  counts	  (>	  three	  interquartile	  range	  above	  the	  median)	  were	  excluded	  due	  to	  presumptive	  sequencing	  error.	  	  Variants	  with	  low	  mean	  depth	  (<8)	  and	  low	  call	  rate	  (<95%)	  were	  excluded.	  	  
Replication	  Cohort	  Selection	  To	  replicate	  our	  findings,	  we	  selected	  samples	  from	  an	  additional	  unrelated	  1,245	  individuals	  with	  historically	  high	  and	  low	  HDL-­‐C	  who	  had	  participated	  in	  other	  genetic	  studies	  related	  to	  lipids.	  Plasma	  lipid	  levels	  were	  measured	  and	  individuals	  with	  HDL-­‐C	  levels	  greater	  than	  the	  95th	  percentile	  (n	  =	  580,	  mean	  HDL	  =	  98	  mg/dl)	  or	  below	  the	  25th	  percentile	  (n	  =	  514,	  mean	  HDL-­‐C	  =	  32	  mg/dl)	  were	  selected	  for	  follow	  up	  (Table	  2).	  	  	  
Exome	  Array	  Genotyping	  Exome	  array	  is	  a	  genotyping	  chip	  designed	  to	  query	  rare	  variation	  in	  the	  European	  population.	  We	  contributed	  a	  small	  number	  of	  variants	  to	  the	  design	  of	  this	  array	  by	  depositing	  128	  variants	  from	  preliminary	  HDL-­‐C	  targeted	  sequencing	  analyses	  with	  marginally	  significant	  (P<0.05)	  results	  for	  variants	  with	  a	  MAF	  <5%	  and	  low-­‐frequency	  nonsynonymous	  variants	  contributing	  to	  significant	  (P<0.05)	  gene	  burden	  test	  results.	  	   Exome	  array	  genotyping	  was	  performed	  at	  the	  Center	  for	  Applied	  Genomics	  at	  the	  Children's	  Hospital	  of	  Pennsylvania.	  	  Genotyping	  calls	  were	  generated	  using	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Genome	  Studio	  and	  all	  samples	  had	  a	  call	  rate	  >98%.	  	  To	  improve	  genotype	  calling	  for	  rare	  variants	  on	  the	  exome	  array,	  uncalled	  sites	  were	  recalled	  using	  zCall,	  which	  has	  been	  described	  in	  detail	  elsewhere.87	  	  Briefly, zCall is a rare-variant caller that 
models the relationship between intensity profiles of common allele homozygote and 
heterozygote clusters at common sites, and then uses these models to assign rare 
genotypes marked as missing in an initial Genome Studio analysis.	  	  
Replication	  Cohort	  Quality	  Control	  All	  samples	  had	  a	  high	  call	  rate	  (>98%).	  	  Six	  samples	  had	  heterozygosity	  rates	  three	  interquartile	  ranges	  above	  the	  median	  and	  were	  excluded.	  	  Population	  clustering	  was	  assessed	  through	  multidimensional	  scaling	  using	  pruned	  common	  variants	  (>5%	  minor	  allele	  frequency)	  that	  were	  not	  in	  linkage	  disequilibrium.	  	  No	  samples	  were	  excluded	  based	  on	  this	  metric.	  	  Individuals	  that	  were	  determined	  to	  have	  a	  high	  degree	  of	  relatedness	  through	  identity-­‐by	  descent	  calculation	  (Pi-­‐Hat	  >	  0.4)	  were	  also	  removed	  from	  the	  analysis.	  	  
Statistical	  Analysis	  Single	  variant	  association	  results	  were	  computed	  using	  adaptive	  permutations	  on	  a	  dichotomous	  phenotype	  of	  high	  and	  low	  levels	  HDL-­‐C	  using	  Fisher’s	  exact	  test.	  	  For	  the	  exome	  array	  genotyping	  cohort,	  clustering	  algorithms	  based	  on	  pruned	  genotypes	  were	  used	  to	  account	  for	  ancestry	  differences	  and	  to	  serve	  as	  a	  sensitivity	  analysis.	  	  Using	  a	  minor	  allele	  frequency	  cutoff	  of	  5%,	  the	  C-­‐alpha88	  and	  variable	  threshold89	  gene	  burden	  tests	  was	  used	  to	  identify	  significantly	  associated	  genes	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with	  a	  Bonferroni	  corrected	  P	  value	  based	  on	  the	  total	  number	  of	  genes	  sequenced	  at	  the	  same	  locus.	  	  The	  C-­‐alpha	  test	  is	  a	  gene	  burden	  test	  that	  aggregates	  variants	  within	  a	  gene	  to	  identify	  if	  a	  mixture	  of	  non-­‐neutral	  alleles	  (risk	  and/or	  protective	  allele)	  are	  present	  that	  result	  in	  a	  deviation	  from	  variance	  expected	  under	  binomial	  model.90	  	  With	  the	  variable	  threshold	  test,	  the	  allele	  frequency	  threshold	  on	  which	  variants	  are	  pooled	  within	  a	  gene	  is	  optimized	  and	  the	  pooled	  variants	  are	  assigned	  equal	  weight	  and	  directionality	  in	  burden	  to	  calculate	  their	  collective	  burden.91	  	  All	  single	  variant	  associations	  and	  gene-­‐based	  associations	  with	  a	  P	  value	  <	  0.05	  were	  compared	  with	  respective	  association	  results	  in	  the	  genotyping	  replication	  population.	  	  All	  analyses	  were	  performed	  using	  R,92	  	  GATK,93	  	  PLINK,94	  	  PLINK/SEQ.95	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HDL-­‐C	  (mg/dl)	   31.6	   101.8	  
LDL-­‐C	  (mg/dl)	   103.1	   123.3	  
TG	  (mg/dl)	   155.2	   75.4	  
Age	  (years)	   63	   60	  
Female	  (%)	   58%	   60%	  
Body	  mass	  index	  (kg/m2)	   28.8	   23.4	  
Type	  II	  Diabetes	  (%)	   6.4%	   5.2%	  Mean	  phenotypic	  characteristics	  of	  individuals	  with	  low	  HDL-­‐C	  (<25th	  percentile)	  and	  high	  HDL-­‐C	  (>95th	  percentile)	  who	  underwent	  targeted	  sequencing.	  	  All	  individuals	  who	  underwent	  targeted	  sequencing	  were	  of	  European	  ancestry.	  	  
Single	  Variant	  Association	  Analysis	  from	  Sequence	  Data	  We	  first	  tested	  the	  association	  of	  individual	  variants	  with	  plasma	  HDL-­‐C.	  	  Quantile-­‐quantile	  plots	  of	  the	  single	  variant	  association	  results	  show	  that	  most	  of	  the	  variants	  fall	  along	  the	  expected	  null	  distribution,	  indicating	  that	  the	  study	  is	  well	  calibrated.	  	  A	  small	  fraction	  of	  variants	  (n=122	  coding	  variants)	  displayed	  nominal	  evidence	  for	  association	  (P<0.05).	  	  Of	  these,	  9	  were	  loss-­‐of-­‐function	  mutations	  (stop	  gained,	  frameshift,	  splicesite)	  and	  113	  were	  missense	  mutations.	  	  The	  variants	  with	  the	  lowest	  P	  values	  were	  in	  genes	  with	  well-­‐characterized	  roles	  in	  HDL	  metabolism	  including	  CETP,	  ABCA1,	  and	  APOA1.	  	  The	  rare,	  nonsense	  variant	  with	  the	  strongest	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association	  evidence	  was	  in	  the	  PPP1R15A	  gene	  (E118X,	  0.4%	  frequency,	  OR	  for	  high	  HDL-­‐C	  of	  9.81,	  P=	  0.04).	  The	  rare,	  missense	  or	  splice-­‐site	  variant	  with	  the	  strongest	  association	  evidence	  was	  in	  the	  CETP	  gene	  (A330P,	  3.3%	  frequency,	  OR	  for	  high	  HDL-­‐C	  of	  0.23,	  P=1.0	  x	  10-­‐5).	  	  
Gentoyping-­‐based	  Replication	  of	  Single	  Variant	  Results	  	   One	  proposed	  method	  for	  testing	  low-­‐frequency	  and	  rare	  DNA	  variation	  is	  to	  first	  sequence	  to	  discover	  variation	  and	  then,	  subsequently,	  to	  genotype	  the	  discovered	  variants	  in	  a	  larger	  number	  of	  individuals	  to	  test	  for	  association	  with	  phenotype.	  	  Towards	  this	  end,	  we	  had	  contributed	  rare	  variants	  identified	  to	  be	  marginally	  significant	  in	  preliminary	  single	  variant	  and	  gene	  burden	  analyses	  from	  targeted	  sequencing	  to	  the	  design	  of	  the	  exome	  genotyping	  array.	  	  The	  final	  designed	  content	  of	  the	  array	  captures	  38%	  of	  the	  variants	  with	  MAF	  <	  5%	  from	  the	  HDL-­‐targeted	  sequencing.	  	  We	  also	  evaluated	  the	  extent	  to	  which	  the	  array	  captured	  all	  of	  the	  low-­‐frequency	  and	  rare	  variants	  discovered	  from	  the	  targeted	  sequencing.	  	  Of	  the	  8,714	  missense,	  nonsense,	  and	  splice-­‐site	  variants	  discovered	  from	  the	  targeted	  sequencing	  of	  719	  individuals,	  43%	  were	  present	  on	  the	  final	  designed	  content	  of	  the	  exome	  genotyping	  array.	  	  Of	  the	  1,250	  individuals	  who	  underwent	  exome	  array	  genotyping,	  1,228	  remained	  after	  sample	  quality	  control	  measures.	  	  Of	  this	  group,	  1,094	  individuals	  had	  HDL-­‐C	  values	  at	  above	  the	  95th	  percentile	  or	  below	  the	  25th	  percentile	  adjusted	  for	  age	  and	  sex.	  	  The	  final	  exome	  array	  genotyping	  association	  analysis	  was	  performed	  on	  580	  individuals	  with	  low	  HDL-­‐C	  levels	  (mean	  HDL-­‐C	  =	  32.0	  mg/dL)	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and	  514	  individuals	  with	  very	  high	  HDL-­‐C	  level	  (mean	  HDL-­‐C	  =	  97.9	  mg/dL)	  (Table	  
2).	  	  	   In	  the	  single	  variant	  analysis	  of	  the	  exome	  array	  genotyping	  data,	  we	  found	  3,638	  coding	  variants	  to	  be	  marginally	  significant	  (P<0.05).	  	  Of	  these,	  167	  were	  loss	  of	  function	  mutations	  and	  3,472	  were	  missense	  mutations.	  	  Of	  the	  significant	  coding	  variants,	  116	  were	  in	  the	  vicinity	  of	  the	  47	  HDL-­‐C	  loci.	  Quantile-­‐quantile	  plots	  were	  well	  calibrated.	  	  	   Of	  the	  122	  coding	  variants	  associated	  with	  HDL-­‐C	  at	  nominal	  significance	  in	  the	  targeted	  sequencing	  single	  variant	  analysis,	  31	  were	  available	  for	  replication	  on	  the	  exome	  array	  data.	  	  Of	  these,	  14	  variants	  in	  the	  genes	  ZNF259,	  APOA5,	  CCDC92,	  
CETP,	  FBN3,	  SNX21,	  APOB,	  TBL2,	  and	  LPL	  also	  showed	  a	  P<0.05	  in	  the	  exome	  array	  association	  analysis.	  	  	  	   Across	  discovery	  and	  replication,	  3	  variants	  associated	  with	  HDL-­‐C	  after	  accounting	  for	  the	  31	  variants	  tested	  (threshold	  P<1.6	  x	  10-­‐3):	  	  the	  A390P	  variant	  in	  
CETP	  (4%	  frequency,	  OR	  for	  high	  HDL-­‐C	  of	  0.33,	  P=2.0	  x	  10-­‐6,	  CETP	  locus),	  the	  S19W	  variant	  in	  APOA5	  (7%	  frequency,	  OR	  for	  high	  HDL-­‐C	  of	  1.78,	  P=8.1	  x	  10-­‐4,	  APOA1	  locus),	  and	  the	  S474X	  variant	  in	  LPL	  (9%	  frequency,	  OR	  for	  high	  HDL-­‐C	  of	  1.66,	  P=1.5	  x	  10-­‐3,	  LPL	  locus).	  	  All	  3	  variants	  have	  been	  previously	  studied.96-­‐98	  (Table	  3)	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HDL-­‐C	  (mg/dl)	   31.7	   98.1	  
LDL-­‐C	  (mg/dl)	   103.4	   121.3	  
TG	  (mg/dl)	   343.6	   78.6	  
Age	  (years)	   49	   57	  
Female	  (%)	   58%	   65%	  
Body	  mass	  index	  (kg/m2)	   32.6	   23.5	  
Type	  II	  Diabetes	  (%)	   26.1%	   3.9%	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Table	  3:	  Top	  Single	  Variant	  Association	  Results	  Including	  Discovery	  and	  
Replication	  




	  Exome	  Array	  
Locus	  
CETP	   16:57015091	   ALA390PRO	   0.04	   0.33	   6.8	  x	  10-­‐5	   2.0	  x	  10-­‐6*	   CETP	  
APOA5	   11:116662407	   SER19TRP	   0.07	   1.78	   4.6	  x	  10-­‐2	   8.1	  x	  10-­‐4*	   APOA1	  
LPL	   8:19819724	   SER474stop	   0.09	   1.66	   3.0	  x	  10-­‐3	   1.5	  x	  10-­‐3*	   LPL	  
ZNF259	   11:116655600	   ALA264VAL	   0.06	   0.58	   3.6	  x	  10-­‐2	   2.9	  x	  10-­‐3	   APOA1	  
CETP	   16:57016092	   VAL422ILE	   0.36	   0.76	   3.3	  x	  10-­‐4	   5.0	  x	  10-­‐3	   CETP	  
APOB	   2:21231524	   PRO2739LEU	   0.22	   1.31	   2.6	  x	  10-­‐2	   9.0	  x	  10-­‐3	   APOB	  
CCDC92	   12:124427306	   SER70CYS	   0.33	   0.79	   8.0	  x	  10-­‐3	   1.2	  x	  10-­‐2	   ZNF664	  
SNX21	   20:44469698	   ALA290THR	   0.003	   5.66	   3.8	  x	  10-­‐2	   1.4	  x	  10-­‐2	   PLTP	  
TBL2	   7:72985148	   VAL345ILE	   0.05	   0.61	   2.7	  x	  10-­‐2	   1.8	  x	  10-­‐2	   MLXIPL	  
FBN3	   19:8176945	   SER1293GLY	   0.18	   1.33	   3.8	  x	  10-­‐2	   2.1	  x	  10-­‐2	   ANGPTL4	  Association	  results	  from	  exome	  array	  replication	  for	  variants	  were	  found	  to	  have	  P	  value	  <	  0.05	  in	  targeted	  sequencing	  single	  variant	  analysis	  and	  exome	  array	  genotyping	  single	  variant	  analysis;	  *indicates	  association	  significant	  after	  Bonferroni	  correction	  for	  number	  of	  variants	  tested;	  REF=Reference	  allele,	  ALT=Alternate	  allele,	  MAF=minor	  allele	  frequency,	  OR=odds	  ratio,	  Locus=gene	  name	  assigned	  to	  HDL-­‐C	  GWA	  SNP70	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Gene-­‐level	  Association	  Analysis	  Using	  Sequence	  and	  Genotype	  Data	  As	  the	  majority	  of	  the	  queried	  variants	  are	  rare,	  we	  collapsed	  the	  missense,	  nonsense,	  and	  splice	  site	  mutations	  in	  each	  gene	  and	  performed	  gene	  burden	  testing.	  	  The	  analysis	  of	  the	  targeted	  sequencing	  data	  using	  the	  variable	  threshold	  test	  found	  12	  genes	  at	  nominal	  significance	  (P<0.05)	  and	  one	  gene,	  SPDEF	  (P=8.0	  x	  10-­‐4),	  to	  achieve	  significance	  after	  Bonferroni	  correction	  for	  number	  of	  genes	  tested	  within	  respective	  HDL-­‐C	  GWAS	  locus.	  	  Performing	  the	  variable	  threshold	  test	  in	  the	  exome	  array	  genotyping	  data	  found	  19	  genes	  to	  be	  marginally	  significant	  (P<0.05)	  and	  three	  genes	  to	  achieve	  significance	  after	  Bonferroni	  correction	  for	  the	  number	  of	  genes	  tested	  within	  their	  respective	  HDL-­‐C	  loci	  (LILRB2	  (P=8.6	  x	  10-­‐5),	  LIPG	  (P=3.0	  x	  10-­‐3),	  and	  SCARB1	  (P=1.0	  x	  10-­‐3)).	  	  Marginally	  significant	  associations	  in	  
CETP	  (15	  pooled	  variants,	  P	  =	  1.1	  x	  10-­‐2),	  LIPG	  (14	  pooled	  variants,	  P=3.0	  x	  10-­‐3),	  and	  
NCOR2	  (52	  pooled	  variants,	  P=3.4	  x	  10-­‐2)	  identified	  using	  the	  variable	  threshold	  test	  in	  the	  targeted	  sequencing	  data	  were	  replicated	  in	  the	  exome	  array	  genotyping	  cohorts	  (Table	  4).	  To	  accommodate	  genes	  where	  variants	  could	  have	  both	  gain-­‐of-­‐function	  and	  loss-­‐of-­‐function	  variants	  affects	  HDL-­‐C,	  we	  performed	  the	  c-­‐alpha	  test	  using	  nonsense,	  missense,	  and	  splice	  site	  variants	  with	  a	  minor	  allele	  frequency	  lower	  than	  5%.	  	  The	  analysis	  of	  the	  targeted	  sequence	  data	  using	  the	  c-­‐alpha	  test	  showed	  that	  11	  genes	  were	  marginally	  significant	  (P<0.05),	  and	  2	  genes	  reached	  significance	  after	  Bonferroni	  correction	  for	  the	  number	  of	  genes	  tested	  within	  their	  respective	  HDL-­‐C	  loci:	  	  ABCA1	  (1.4	  x	  10-­‐4)	  and	  CETP	  (P=1.3	  x	  10-­‐5).	  	  Performing	  the	  c-­‐alpha	  test	  on	  the	  exome	  array	  genotyping	  data	  using	  the	  same	  inclusion	  criteria	  showed	  that	  
	   28	  
19	  genes	  were	  marginally	  significant	  and	  five	  genes	  reached	  significance	  after	  Bonferroni	  correction	  for	  the	  number	  of	  genes	  tested	  within	  their	  respective	  HDL-­‐C	  loci:	  CD40	  (P=3.4	  x	  10-­‐4),	  CETP	  (P=2.0	  x	  10-­‐6),	  LILRB2	  (P=2.1	  x	  10-­‐5),	  PLG	  (P=8.9	  x	  10-­‐
5),	  and	  TCAP	  (P=1.0	  x	  10-­‐3).	  	  The	  marginally	  significant	  association	  identified	  in	  CETP	  (P=2.0	  x	  10-­‐6)	  using	  the	  c-­‐alpha	  test	  in	  targeted	  sequencing	  was	  replicated	  in	  the	  exome	  array	  genotyping	  analysis	  (Table	  4).	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Table	  4:	  Top	  gene-­‐level	  association	  results	  after	  discovery	  and	  replication	  









chr16:56995908..57017292	   CETP	   CALPHA/VT	   1.3	  x	  10-­‐5/	  2.0	  x	  10-­‐2	   2.0	  x	  10-­‐6	  /1.1	  x	  10-­‐2	  
chr18:47088754..47109955	   LIPG	   VT	   1.6	  x	  10-­‐2	   3.0	  x	  10-­‐3	  
chr12:124810093..124979749	   NCOR2	   VT	   1.9	  x	  10-­‐2	   3.4	  x	  10-­‐2	  
Association	  results	  from	  exome	  array	  replication	  for	  pooling	  of	  variants	  led	  to	  gene-­‐based	  associations	  with	  P	  <0.05	  in	  targeted	  sequencing	  burden	  analysis	  and	  exome	  array	  genotyping	  burden	  analysis	  using	  C-­‐alpha	  and	  variable	  threshold	  tests	  (VT).	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DISCUSSION	  We	  identified	  47	  GWAS	  loci	  for	  HDL-­‐C,	  targeted	  all	  exons	  at	  407	  genes	  within	  these	  genomic	  regions,	  sequenced	  individuals	  with	  extremely	  high	  or	  low	  HDL-­‐C,	  and	  attempted	  replication	  in	  an	  independent	  sample	  through	  array-­‐based	  genotyping.	  	  After	  performing	  single	  variant	  and	  gene-­‐burden	  analyses	  across	  discovery	  and	  replication	  cohorts,	  we	  did	  not	  identify	  any	  new	  rare	  coding	  sequence	  variants	  or	  genes	  with	  a	  large	  effect	  on	  plasma	  HDL-­‐C	  levels.	  	  This	  study	  was	  successful	  in	  replicating	  known	  genes	  with	  previously	  defined	  associations	  with	  plasma	  lipid	  levels.	  	  The	  functions	  of	  CETP,	  APOA5,	  LPL,	  APOB,	  and	  
LIPG	  in	  HDL-­‐C	  metabolism	  have	  been	  well	  established.63,97-­‐100	  Although	  the	  functional	  role	  of	  the	  CCD92	  and	  ZNF259	  genes	  remain	  unclear,	  these	  loci	  have	  previously	  been	  associated	  with	  plasma	  lipoprotein	  size,	  concentration,	  and	  cholesterol	  content.73	  The	  study	  permits	  several	  conclusions.	  	  First,	  since	  we	  were	  unable	  pinpoint	  specific	  coding	  variants	  responsible	  for	  the	  genome-­‐wide	  association	  signals	  for	  HDL-­‐C,	  we	  can	  speculate	  that	  the	  GWAS	  association	  signals	  may	  be	  truly	  due	  to	  non-­‐coding,	  regulatory	  variants.	  	  Of	  the	  47	  total	  HDL	  GWAS	  loci	  that	  were	  fine	  mapped,	  36	  loci	  (77%)	  remain	  without	  any	  marginally	  significant	  single	  coding	  variant	  or	  gene-­‐based	  association.	  	  Only	  the	  S70C	  variant	  in	  CCDC92	  and	  the	  P2739L	  variant	  in	  
APOB	  were	  found	  to	  have	  identical	  minor	  allele	  frequencies	  and	  similar	  effect	  size	  estimates	  as	  the	  non-­‐coding	  variants	  in	  their	  respective	  GWAS	  loci	  (APOB locus: 
rs1042034, frequency = 22%, effect = +4.16 mg/dL, P = 4.08 x 10-96 with APOB variant 
P2739L, frequency = 22%, OR = 1.31, P = 2.6 x 10-2 and ZNF664 locus: rs4765127, 
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frequency = 34%, effect = +0.44 mg/dL, P = 2.89 x 10-10 with CCDC92 variant S70C, 
frequency = 36%, OR = 0.79, P = 8.0 x 10-3).70	  	  This	  suggests	  that	  for	  these	  two	  loci,	  the	  identified	  coding	  variants	  may	  be	  responsible	  for	  the	  initial	  common	  noncoding	  variant	  GWAS	  association.	  	  For	  the	  remaining	  loci,	  intronic	  or	  intergenic	  SNPs	  in	  vicinity	  of	  the	  HDL-­‐C	  GWAS	  loci	  may	  be	  involved	  in	  regulation	  and	  expression	  of	  coding	  genes	  involved	  in	  lipid	  metabolism.101	  Secondly,	  targeted	  sequencing	  may	  have	  limited	  utility	  in	  discovering	  functional	  causes	  of	  GWAS	  signals.	  	  The	  absence	  of	  rare	  coding	  variants	  of	  large	  effect	  in	  GWAS	  loci	  is	  consistent	  with	  reports	  from	  other	  groups	  who	  have	  performed	  targeted	  sequencing-­‐based	  variant	  discovery	  and	  genotyping-­‐based	  replication	  studies	  to	  investigate	  variants	  in	  GWAS	  loci	  for	  autoimmune	  diseases	  with	  larger	  sample	  sizes.102	  	  Although	  targeted	  sequencing	  has	  previously	  been	  used	  to	  identify	  a	  few	  genes	  implicated	  in	  various	  diseases,	  hundreds	  of	  GWAS	  loci	  have	  collectively	  been	  fine	  mapped	  in	  the	  course	  of	  these	  studies,	  and	  the	  functional	  significance	  of	  the	  association	  signal	  at	  the	  vast	  majority	  of	  these	  loci	  remains	  unresolved.76-­‐78,83	  Therefore	  revisiting	  and	  systematically	  studying	  the	  initially	  discovered	  non-­‐coding	  variants	  in	  the	  implicated	  loci	  will	  be	  necessary	  to	  better	  understand	  the	  biologic	  underpinnings	  of	  these	  associations.	  Several	  limitations	  of	  the	  present	  study	  need	  to	  be	  considered.	  	  The	  collective	  sample	  size	  of	  719	  individuals	  may	  be	  too	  small	  to	  provide	  sufficient	  power	  to	  detect	  associations	  of	  rare	  alleles	  with	  more	  modest	  effect.	  The	  targeted	  sequencing	  analysis	  has	  80%	  power	  to	  identify	  0.7%	  frequency	  variants	  with	  odds	  ratio	  greater	  than	  3.25,	  1%	  frequency	  variants	  with	  odds	  ratio	  greater	  than	  2.56,	  and	  5%	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frequency	  variants	  with	  an	  odds	  ratio	  of	  greater	  than	  1.47	  in	  the	  study	  population.103	  	  	  However,	  the	  total	  number	  of	  individuals	  in	  the	  study	  is	  similar	  to	  the	  sample	  sizes	  studied	  for	  the	  analysis	  of	  different	  traits	  by	  other	  groups	  who	  were	  able	  to	  implicate	  coding	  mutations	  to	  GWAS	  SNPS	  using	  fine	  mapping	  and	  replication.76-­‐78,83	  	  	  Furthermore,	  the	  replication	  study	  was	  performed	  using	  exome	  array	  genotyping	  rather	  than	  additional	  sequencing.	  	  As	  a	  result,	  we	  were	  unable	  to	  fully	  test	  the	  following:	  	  1)	  rare	  variants	  discovered	  in	  the	  targeted	  sequencing	  but	  not	  present	  on	  the	  exome	  array:	  and	  2)	  a	  model	  where	  a	  burden	  of	  multiple	  rare	  alleles	  exclusively	  contributes	  to	  association	  signal.	  	  	  	   Although	  this	  study	  successfully	  identified	  common	  variants	  and	  genes	  previously	  implicated	  in	  HDL-­‐C	  metabolism,	  we	  did	  not	  identify	  any	  new	  rare	  coding	  variants	  or	  genes	  with	  sufficiently	  significant,	  replicating	  associations	  in	  the	  47	  loci	  with	  genome-­‐wide	  associations	  with	  HDL-­‐C.	  	  Fine	  mapping	  of	  coding	  regions	  surrounding	  GWAS	  loci	  may	  have	  limited	  utility	  in	  the	  investigation	  of	  the	  cause	  of	  these	  association	  signals.	  	  Though	  the	  study	  may	  have	  been	  limited	  by	  power	  and	  its	  genotying-­‐based	  replication,	  it	  suggests	  that	  noncoding	  variation	  may	  be	  playing	  a	  significant	  role	  in	  determining	  plasma	  HDL-­‐C	  levels.	  	  These	  results	  provide	  insight	  regarding	  the	  design	  of	  similar	  sequencing	  studies	  for	  cardiovascular	  traits	  with	  respect	  to	  sample	  size,	  follow-­‐up,	  and	  analysis	  methodology.	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Part	  II:	  	  Plasma	  Lipids	  Association	  Study	  Including	  ~130,000	  Individuals	  
Genotyped	  Using	  the	  Exome	  Array	  	  
	  
BACKGROUND	  	  	  	  	   Plasma	  low-­‐density	  lipoprotein	  cholesterol	  (LDL-­‐C),	  high-­‐density	  lipoprotein	  cholesterol	  (HDL-­‐C),	  and	  triglycerides	  (TG)	  are	  quantitative,	  heritable	  risk	  factors	  for	  coronary	  heart	  disease.3	  Linkage	  and	  sequencing	  studies	  have	  identified	  a	  number	  of	  very	  rare	  variants	  in	  genes	  implicated	  in	  Mendelian	  dyslipidemias.61-­‐63,66	  	  Genome-­‐wide	  association	  (GWA)	  studies	  have	  identified	  many	  common	  single	  nucleotide	  polymorphisms	  (SNPs)	  associated	  with	  plasma	  lipid	  levels.16,66,67,69,70,72-­‐74	  However,	  the	  impact	  of	  rare	  and	  low	  frequency	  variation	  on	  plasma	  lipid	  levels	  in	  the	  population	  remains	  largely	  unstudied	  due	  to	  logistical	  limitations	  of	  current	  methodology.	  	  Querying	  this	  range	  of	  variation	  may	  help	  provide	  potential	  novel	  targets	  for	  therapeutics	  for	  preventing	  and	  treating	  coronary	  heart	  disease.	  	  	   A	  large	  cohort	  of	  samples	  is	  necessary	  to	  sufficiently	  power	  a	  study	  to	  detect	  rare	  associations,	  and	  exome	  sequencing	  on	  this	  scale	  is	  currently	  prohibitively	  expensive.	  	  	  Other	  groups	  have	  designed	  custom	  arrays	  for	  fine	  mapping	  and	  candidate	  gene	  genotyping	  of	  large	  cohorts	  of	  individuals	  with	  cardiovascular,	  metabolic,	  and	  immunologic	  diseases.104-­‐106	  A	  consortium	  of	  groups	  studying	  a	  broad	  range	  of	  diseases	  has	  taken	  a	  similar	  approach	  with	  a	  broader	  stroke	  of	  attempting	  to	  capture	  all	  replicable	  rare	  and	  low	  frequency	  variants	  from	  the	  entire	  exome	  on	  an	  array	  based	  on	  the	  variation	  seen	  in	  exome	  sequencing	  of	  over	  12,000	  individuals.	  	  As	  this	  array	  makes	  the	  analysis	  of	  variants	  in	  tens	  of	  thousands	  of	  individuals	  considerably	  faster	  and	  less	  expensive,	  it	  lends	  itself	  to	  interrogating	  rare	  and	  low	  frequency	  variants	  in	  complex	  traits	  via	  large	  collaborative	  efforts.	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HYPOTHESIS	  AND	  SPECIFIC	  AIMS	  
We	  hypothesized	  that	  using	  a	  novel	  genotyping	  array	  focusing	  on	  low-­‐frequency	  and	  rare	  variants,	  we	  can	  discover	  new	  genes	  and	  variants	  associated	  with	  plasma	  lipid	  levels.	  	  Our	  specific	  aims	  were	  as	  follows:	  
1).	  Contributed	  to	  the	  to	  the	  design	  of	  the	  exome	  array.	  
2).	  Obtained	  plasma	  lipid	  level	  data	  and	  performed	  genotyping	  and	  data	  	  
processing	  in	  all	  participating	  cohorts.	  	  
3).	  Analyzed	  data	  from	  each	  cohort	  using	  a	  common	  analysis	  plan.	  
4).	  Combined	  test	  statistics	  from	  participating	  studies	  and	  meta-­‐analyzed	  results	  in	  single	  variant	  and	  gene	  based	  testing.	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METHODS	  
Cohort	  Selection	  	   The	  more	  than	  130,000	  samples	  that	  were	  genotyped	  and	  analyzed	  came	  from	  58	  cohorts	  of	  individuals	  from	  around	  the	  world.	  	  These	  cohorts	  consist	  of	  cases	  and	  controls	  for	  early	  onset	  myocardial	  infarction	  and	  type	  2	  diabetes	  mellitus,	  as	  well	  as	  members	  of	  the	  general	  population.	  	  The	  majority	  of	  these	  individuals	  report	  having	  European	  ancestry	  while	  a	  significant	  portion	  report	  South	  Asian	  and	  African	  ancestries.	  	  
Phenotype	  Modeling	  	   Plasma	  lipid	  trait	  data	  was	  collected	  and	  modeled	  uniformly	  across	  all	  cohorts.	  	  Blood	  was	  collected,	  plasma	  lipid	  levels	  were	  measured,	  and	  DNA	  was	  extracted	  from	  each	  study	  participant’s	  blood	  sample.	  	  Only	  individuals	  who	  had	  blood	  drawn	  while	  fasting	  were	  included	  in	  the	  analysis	  of	  LDL-­‐C	  and	  TG.	  	  All	  individuals	  were	  included	  in	  the	  analysis	  of	  HDL-­‐C,	  regardless	  of	  fasting	  status	  at	  the	  time	  of	  blood	  draw.	  	  Calculations	  involving	  LDL-­‐C,	  HDL-­‐C	  values	  were	  performed	  using	  units	  of	  mg/dl,	  and	  calculations	  involving	  TG	  were	  performed	  using	  the	  natural	  log	  transform	  of	  the	  TG	  level	  in	  mg/dl.	  	  The	  mean	  levels	  for	  each	  trait	  across	  the	  cohorts	  were	  representative	  of	  the	  general	  population	  (LDL-­‐C:	  161	  mg/dl,	  HDL-­‐C:	  53	  mg/dl,	  TG:	  107	  mg/dl,	  and	  TC:	  239	  mg/dl).	  	  For	  data	  collected	  after	  1994,	  the	  plasma	  TC	  measurements	  of	  subjects	  that	  were	  known	  to	  be	  on	  lipid	  medication	  were	  adjusted	  (adjusted	  TC	  =	  TC	  /	  0.8)	  with	  the	  assumption	  that	  they	  were	  prescribed	  statins	  following	  the	  publication	  of	  the	  4S	  trial.49	  	  For	  data	  that	  was	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collected	  prior	  to	  1994,	  no	  adjustments	  were	  made	  to	  account	  for	  lipid	  medication.	  	  LDL-­‐C	  was	  calculated	  using	  the	  Friedewald	  formula	  for	  individuals	  with	  a	  triglyceride	  level	  <	  400	  mg/dl	  (LDL	  =	  TC	  –	  HDL	  –	  (TG/5)).36	  	  For	  individuals	  whose	  TC	  levels	  were	  modified	  due	  to	  lipid	  medication	  status,	  the	  modified	  TC	  was	  used	  in	  the	  formula.	  	  Regardless	  of	  medication	  status,	  no	  adjustments	  were	  made	  for	  HDL-­‐C	  or	  TG.	  	   For	  each	  lipid	  trait,	  residuals	  were	  calculated	  after	  adjusting	  for	  age,	  age2,	  sex,	  and	  at	  least	  4	  principal	  components	  computed	  through	  multiple	  dimensional	  scaling.	  	  The	  inverse	  normal	  transformation	  of	  the	  trait	  residuals	  served	  as	  the	  phenotypes	  in	  the	  analysis.	  	  
Exome	  Array	  Design	  	   Exome	  array	  is	  a	  genotyping	  chip	  designed	  to	  query	  rare	  variation	  down	  to	  1:10,000	  in	  the	  European	  population.	  	  The	  array	  includes	  coding	  variants	  seen	  in	  multiple	  existing	  sequence	  datasets	  of	  ~12,000	  sequenced	  genomes	  and	  exomes	  of	  individuals	  of	  mainly	  European	  ancestry.	  	  It	  also	  contains	  all	  of	  the	  variants	  implicated	  in	  GWAS	  found	  in	  the	  NHGRI	  catalog	  and	  a	  small	  amount	  of	  insertion-­‐deletions,	  micro	  RNA	  target	  sites,	  mitochondrial	  variants,	  and	  ancestry	  markers.	  	  A	  more	  detailed	  description	  of	  exome	  array	  SNP	  content	  and	  selection	  is	  available	  on	  the	  design	  website.107	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Exome	  Array	  Genotyping	  Exome	  array	  genotyping	  was	  performed	  at	  academic	  institutes	  around	  the	  world	  using	  Illumina	  HumanExome	  BeadChip	  arrays.	  	  All	  genotypes	  were	  called	  using	  zCall,	  a	  variant	  caller	  specifically	  designed	  for	  calling	  rare	  SNPs	  from	  the	  exome	  array.87	  	  	  This	  caller	  was	  implemented	  as	  a	  post-­‐processing	  step	  after	  a	  default	  autocalling	  algorithm	  was	  applied.	  Linear	  regression	  was	  used	  to	  determine	  the	  relationship	  between	  the	  intensity	  profile	  of	  the	  common	  allele	  homozygote	  clusters	  for	  common	  sites,	  and	  an	  optimal	  z	  value	  was	  obtained,	  which	  was	  then	  used	  to	  recall	  the	  genoypes	  at	  each	  site.	  
	  
Genotyping	  Quality	  Control	  	   After	  genotyping,	  each	  cohort	  of	  samples	  underwent	  uniform	  and	  stringent	  quality	  control	  measures.	  	  Samples	  with	  an	  autocall	  rate	  <98%	  or	  a	  Z-­‐call	  rate	  <99%	  were	  removed.	  	  Samples	  with	  a	  high	  heterozygosity	  rate	  (a	  measure	  of	  contamination)	  three	  interquartile	  ranges	  above	  the	  median	  were	  excluded.	  	  Samples	  exhibiting	  gender	  discordance	  were	  removed.	  Population	  clustering	  was	  assessed	  through	  multidimensional	  scaling	  using	  pruned	  common	  variants	  (>5%	  minor	  allele	  frequency)	  that	  were	  not	  in	  linkage	  disequilibrium,	  and	  outliers	  based	  on	  these	  metrics	  were	  excluded.	  	  Individuals	  that	  were	  determined	  to	  have	  a	  high	  degree	  of	  relatedness	  through	  identity-­‐by	  descent	  calculation	  (Pi-­‐Hat	  >	  0.4)	  were	  also	  removed	  from	  the	  analysis.	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Association	  Analysis	  	   Each	  cohort	  was	  analyzed	  independently.	  	  For	  study	  groups	  ascertained	  on	  case	  or	  control	  status	  for	  early	  onset	  myocardial	  infarction	  or	  type	  2	  diabetes,	  the	  two	  sub-­‐groups	  were	  modeled	  as	  separate	  studies.	  	  Each	  self-­‐reported	  racial	  subgroup	  was	  also	  modeled	  as	  a	  separate	  study.	  Single	  variant	  association	  was	  performed	  using	  a	  linear	  regression-­‐based	  analysis	  of	  missense,	  nonsense,	  and	  splice	  variants	  with	  minor	  allele	  frequency	  >1%.	  	  The	  statistical	  software	  programs	  rvtests	  and	  RareMetalWorker	  were	  used	  to	  run	  the	  rare	  variant	  analyses	  and	  to	  generate	  summary	  statistics.	  	  The	  rvtests	  program	  was	  used	  for	  cohorts	  with	  all	  unrelated	  individuals.	  	  RareMetalWorker	  was	  used	  to	  analyze	  cohorts	  that	  included	  related	  individuals	  and	  generated	  an	  empirical	  kinship	  matrix	  based	  on	  the	  cohort’s	  genotype	  data	  to	  account	  for	  hidden	  relatedness	  or	  substructures	  during	  the	  analysis.	  	  Additional	  computation	  was	  performed	  using	  R92	  and	  PLINK.94	  	  The	  summary	  level	  statistics	  generated	  by	  both	  programs	  included:	  	  allele	  frequency	  for	  each	  variant,	  single	  variant	  association	  score	  test	  statistics	  with	  direction	  of	  effect,	  covariance	  matrix	  for	  each	  genetic	  region,	  and	  metrics	  for	  assessing	  genotype	  qualities,	  including	  Hardy	  Weinberg	  equilibrium	  and	  call	  rate.	  	  The	  output	  files	  were	  uniformly	  prepared	  by	  each	  study	  and	  then	  aggregated	  and	  meta-­‐analyzed	  at	  one	  site.	  	   Gene-­‐based	  association	  involving	  burden	  analysis	  of	  pooled	  rare	  variants	  within	  a	  gene	  was	  used	  to	  assess	  if	  rare	  mutations	  in	  aggregate	  associate	  with	  the	  lipid	  traits.	  	  Using	  summary	  statistics	  for	  each	  variant,	  genes	  were	  annotated	  based	  on	  entries	  in	  the	  refFlat/refGene	  database.	  	  Only	  non-­‐synonymous	  variants,	  stop	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gain	  mutations,	  stop	  loss	  mutations,	  and	  splice	  site	  mutations	  with	  minor	  allele	  frequencies	  less	  than	  5%	  were	  used	  in	  separate	  burden	  analyses.	  	  The	  variable	  threshold	  test	  assigns	  equal	  weight	  and	  directionality	  of	  effect	  to	  each	  variant,91	  while	  the	  SKAT	  (Sequence	  Kernel	  Association	  Tests)	  test	  better	  assesses	  the	  effects	  of	  causal	  variants	  with	  opposite	  effects	  present	  in	  a	  gene	  region.108	  	  Both	  analyses	  were	  performed	  for	  each	  cohort,	  and	  the	  results	  were	  meta-­‐analyzed.	  	  	  
Meta-­‐analysis	  	   In	  order	  to	  power	  the	  study	  well,	  very	  large	  sample	  sizes	  from	  a	  collaboration	  of	  groups	  were	  needed.	  	  We	  gathered	  summary	  statistics	  generated	  using	  a	  common	  analysis	  plan	  from	  each	  of	  the	  58	  participating	  studies	  and	  combined	  single	  variant	  test	  statistics	  using	  the	  Mantel-­‐Haenszel	  method.109	  	  We	  then	  subsequently	  meta-­‐analyzed	  gene-­‐level	  association	  tests	  for	  a	  total	  of	  >130,000	  individuals	  using	  RAREMETAL.110	  
	  
Conditional	  Analysis	  As	  all	  variants	  on	  the	  exome	  array	  were	  included	  in	  the	  analysis	  without	  exclusions	  based	  on	  SNPs	  being	  in	  linkage	  disequilibrium,	  conditional	  analysis	  was	  necessary	  to	  identify	  the	  true,	  independent	  association	  signals.	  	  Using	  the	  covariance	  matrices	  generated	  during	  the	  analysis	  step	  for	  each	  cohort,	  each	  variant	  was	  conditioned	  on	  the	  SNP	  with	  the	  lowest	  P	  value	  within	  a	  1	  megabase	  window.	  	  No	  conditional	  analysis	  was	  performed	  for	  the	  SNPs	  with	  the	  strongest	  associations	  in	  a	  1	  megabase	  window	  block.	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RESULTS	  
Single	  Variant	  Analysis	  From	  Exome	  Array	  Genotyping	  After	  stringent	  quality	  control	  measures,	  over	  130,000	  samples	  were	  included	  in	  the	  final	  analysis	  of	  each	  lipid	  trait.	  	  The	  mean	  plasma	  lipid	  levels	  and	  phenotypic	  distributions	  for	  the	  combined	  cohorts	  were	  representative	  of	  the	  general	  population.	  	  All	  participating	  studies	  reported	  excellent	  genotyping	  data	  quality,	  and	  minimal	  samples	  were	  excluded	  during	  the	  quality	  control	  phase.	  	  Quantile-­‐quantile	  plots	  for	  each	  lipid	  trait	  were	  well	  calibrated.	  In	  the	  single	  variant	  analysis	  of	  the	  population	  exome	  array	  genotyping	  data,	  we	  identified	  over	  230,000	  polymorphic	  variants	  each	  for	  LDL,	  HDL,	  and	  TG.	  	  This	  includes	  194,470	  missense	  variants,	  9,600	  splicesite	  variants,	  4,546	  nonsense	  variants,	  76	  frame	  shift	  variants,	  and	  30,894	  non-­‐coding	  variants.	  	  Of	  these,	  27,827	  or	  12.1%	  were	  common	  mutations	  (>5:100	  in	  the	  population),	  48,437	  or	  21.1%	  were	  low	  frequency	  mutations	  (1:1000-­‐5:100	  in	  the	  population),	  and	  153,719	  or	  66.8%	  were	  rare	  mutations	  (<1:1000	  in	  the	  population).	  	  The	  Bonferroni	  cutoff	  for	  statistical	  significance	  was	  determined	  to	  be	  P	  <	  2	  x	  10-­‐7	  for	  single	  variants,	  given	  the	  ~250,000	  variants	  on	  the	  exome	  array	  available	  for	  analysis.	  	  After	  performing	  conditional	  analysis,	  we	  identified	  79	  variants	  associated	  with	  LDL,	  133	  variant	  associated	  with	  HDL,	  and	  97	  variants	  associated	  with	  TG	  that	  met	  Bonferroni	  cutoff	  of	  exome	  array	  wide	  significance.	  	  The	  majority	  of	  these	  findings	  represented	  GWAS	  variants	  that	  had	  been	  reported	  in	  the	  NHGRI	  catalog	  and	  placed	  on	  the	  array.	  	  We	  identified	  low	  frequency	  and	  rare	  variants	  for	  each	  trait	  (10	  SNPs	  for	  LDL,	  29	  SNPs	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for	  HDL,	  15	  SNPs	  for	  TG)	  that	  remained	  statistically	  significant	  after	  conditional	  analysis.	  	  The	  strongest	  associations	  for	  each	  trait	  replicated	  well-­‐established	  associations,	  which	  serve	  as	  positive	  controls	  (Table	  5).	  	  For	  LDL-­‐C,	  variants	  in	  
APOE	  (R176C,	  frequency	  =	  7:100,	  effect=-­‐22.1	  mg/dl,	  P	  <	  9	  x	  10-­‐288)	  and	  PCSK9	  (R46L,	  frequency	  =	  2:100,	  effect=-­‐17.6	  mg/dl,	  P	  =	  1	  x	  10-­‐190)	  were	  the	  top	  coding	  mutation	  signals.	  	  For	  HDL-­‐C,	  the	  top	  hits	  were	  in	  CETP	  (A390P,	  frequency	  =	  4:100,	  effect	  =	  -­‐4.0	  mg/dl,	  P	  =	  1	  x	  10-­‐178)	  and	  LPL	  (S474X,	  frequency	  =	  1:10,	  effect	  =	  +2.5	  mg/dl,	  P	  =	  4	  x	  10-­‐143).	  	  For	  TG,	  the	  top	  hits	  were	  in	  APOA5	  (S19W,	  frequency	  =	  6:100,	  effect	  =	  +14.9	  mg/dl,	  P	  =8	  x	  10-­‐184)	  and	  LPL	  (S474X,	  1:10,	  effect	  =	  11.6	  mg/dl,	  P	  =	  1	  x	  10-­‐170).	  	  The	  roles	  of	  all	  of	  these	  genes	  have	  been	  well	  characterized	  in	  lipid	  metabolism.62,97,98,111,112	  	  All	  of	  these	  variants	  occur	  at	  low	  to	  common	  frequencies	  resulting	  in	  strong	  statistical	  signals.	  
Additionally,	  we	  identified	  11	  new	  genes	  and	  variants	  associated	  with	  plasma	  lipid	  levels	  (Table	  6).	  	  For	  LDL-­‐C,	  we	  identified	  a	  variant	  in	  ABCA6	  (C1359R,	  frequency	  =	  1:100,	  effect=+8.2	  mg/dl,	  P=9.7	  x	  10-­‐32),	  a	  member	  of	  the	  ATP-­‐binding	  cassette	  family,	  associated	  with	  increased	  LDL-­‐C	  levels.	  	  We	  also	  identified	  a	  variant	  in	  SERPINA	  (E366K,	  frequency	  =	  2:100,	  effect	  =	  +3.1	  mg/dl,	  P=2.3	  x	  10-­‐7),	  which	  is	  a	  serine	  protease	  inhibitor,	  and	  a	  variant	  in	  REST	  (R645W,	  frequency	  =	  6:10000,	  effect	  =	  +13.7	  mg/dl,	  P=5.0	  x	  10-­‐7),	  which	  is	  a	  RE1-­‐silencing	  transcription	  factor,	  associated	  with	  increased	  LDL-­‐C	  levels.	  Furthermore	  we	  identified	  a	  variant	  in	  
FBLN1	  (H695R,	  frequency	  =	  2:100,	  effect	  =	  -­‐2.7	  mg/dl,	  P=5.3	  x	  10-­‐7),	  which	  is	  tumor	  
	   42	  
suppressor	  gene,	  and	  a	  variant	  in	  CCDC117	  (T232I,	  frequency	  =	  9:1000,	  effect	  =	  -­‐4.3	  mg/dl,	  P=7.3	  x	  10-­‐7),	  which	  is	  a	  coiled	  coil	  domain,	  associated	  with	  decreased	  LDL-­‐C.	  For	  HDL,	  we	  identified	  a	  variant	  in	  TMED6	  (F6L,	  frequency	  =	  4:100,	  effect	  =	  -­‐0.8	  mg/dl,	  P=4.4	  x	  10-­‐9),	  which	  is	  involved	  in	  transmembrane	  transport	  ,	  and	  a	  variant	  in	  CDC25A	  (Q24H,	  frequency	  =	  3:100,	  effect	  =	  -­‐1.0	  mg/dl,	  P=8.4	  x	  10-­‐8),	  which	  is	  a	  phosphatase	  involved	  in	  cell	  cycle	  regulation,	  associated	  with	  decreased	  HDL-­‐C	  levels.	  Furthermore,	  we	  identified	  a	  variant	  in	  MAP1A,	  a	  microtubule-­‐associated	  protein,	  (P2349L,	  frequency	  =	  3:100)	  associated	  with	  decreased	  HDL-­‐C	  levels	  (effect	  =	  -­‐1.4mg/dl,	  P=3.9	  x	  10-­‐14)	  and	  increased	  triglyceride	  levels	  (effect	  =	  +8.4mg/dl,	  P=3.2	  x	  10-­‐26).	  	  	  For	  TG	  we	  identified	  a	  variant	  in	  PRRC2A	  (S1219Y,	  frequency	  =	  2:100,	  effect	  =	  +6.6	  mg/dl,	  P=4.6	  x	  10-­‐17),	  which	  is	  a	  proline	  rich	  coiled-­‐coil	  ,	  and	  a	  variant	  in	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Table	  5:	  	  Top	  Exome	  Array	  Single	  Variant	  Associations	  
Trait	   Chromsome:	  
Position	   Gene	   Coding	  Change	   P	  Value	   Allele	  Frequency	   Effect	  (mg/dl)	  
LDL	   chr19:45412079	   APOE	   ARG176CYS	   <9.1	  x	  10-­‐288	   7:100	   -­‐22.1	  
LDL	   chr1:55505647	   PCSK9	   ARG46LEU	   1.0	  x	  10-­‐190	   2:100	   -­‐17.6	  
HDL	   chr16:57015091	   CETP	   ALA390PRO	   1.4	  x	  10-­‐178	   4:100	   -­‐4.0	  
HDL	   chr8:19819724	   LPL	   SER474stop	   3.8	  x	  10-­‐143	   1:10	   +2.5	  
TG	   chr11:116662407	   APOA5	   SER19TRP	   7.7	  x	  10-­‐184	   6:100	   +14.9	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Table	  6:	  	  Novel	  Exome	  Array	  Single	  Variant	  Associations	  
Trait	   Chromosome:	  
Position	   Gene	   Coding	  Change	   P	  Value	   Allele	  Frequency	   Effect	  (mg/dl)	  
LDL	   chr17:67081278	   ABCA6	   CYS1359ARG	   9.7	  x	  10-­‐32	   1:100	   +8.2	  
LDL	   chr14:94844947	   SERPINA1	   GLU366LYS	   2.3	  	  x	  10-­‐7	   2:100	   +3.1	  
LDL	   chr4:57796957	   REST	   ARG645TRP	   5.0	  	  x	  10-­‐7	   6:10000	   +13.7	  
LDL	   chr22:45996298	   FBLN1	   HIS695ARG	   5.3	  	  x	  10-­‐7	   2:100	   -­‐2.7	  
LDL	   chr22:29182169	   CCDC117	   THR232ILE	   7.3	  	  x	  10-­‐7	   9:1000	   -­‐4.3	  
HDL	   chr11:116701354	   APOC3	   IVS2+1	  G>A	   3.5	  x	  10-­‐42	   1:1000	   +10.6	  
HDL	   chr11:116701353	   APOC3	   ARG19stop	   9.9	  x	  10-­‐12	   3:10000	   +11.0	  
HDL	   chr15:43820717	   MAP1A	   PRO2349LEU	   3.9	  x	  10-­‐14	   3:100	   -­‐1.4	  
HDL	   chr16:69385641	   TMED6	   PHE6LEU	   4.4	  	  x	  10-­‐9	   4:100	   -­‐0.8	  
HDL	   chr3:48229366	   CDC25A	   GLN24HIS	   8.4	  	  x	  10-­‐8	   3:100	   -­‐1.0	  
TG	   chr11:116701353	   APOC3	   ARG19stop	   5.8	  x	  10-­‐23	   3:10000	   -­‐65.9	  
TG	   chr11:116701354	   APOC3	   IVS2+1	  G>A	   2.0	  x	  10-­‐81	   1:1000	   -­‐65.2	  
TG	   chr15:43820717	   MAP1A	   PRO2349LEU	   3.2	  x	  10-­‐26	   3:100	   +8.4	  
TG	   chr6:31600106	   PRRC2A	   SER1219TYR	   4.6	  x	  10-­‐17	   2:100	   +6.6	  
TG	   chr21:46875817	   COL18A1	   VAL125ILE	   1.3	  	  x	  10-­‐7	   1:1000	   +18.0	  
TG	   chr1:184672098	   EDEM3	   PRO746SER	   2.4	  x	  10-­‐7	   1:100	   -­‐5.4	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In	  addition	  to	  these	  novel	  associations	  with	  genes,	  we	  also	  discovered	  a	  new	  splice	  site	  variant	  in	  the	  gene	  APOC3	  (IVS2+1	  G>A,	  frequency	  =	  1:1000)	  that	  is	  significantly	  associated	  with	  increased	  HDL-­‐C	  levels	  (effect=+10.6mg/dl,	  P=3.5	  x	  10-­‐
42)	  and	  decreased	  TG	  levels	  (effect=-­‐65.2mg/dl,	  P=2.0	  x	  10-­‐81).	  	  Furthermore,	  we	  report	  population	  level	  data	  for	  an	  established	  variant	  in	  APOC3	  (R19X,	  frequency	  =	  3:10,000)	  that	  introduces	  a	  premature	  stop	  codon	  and	  truncates	  the	  protein	  leading	  to	  a	  loss	  of	  function.	  	  This	  variant	  has	  been	  reported	  to	  occur	  at	  a	  5%	  frequency	  in	  the	  Lancaster	  Amish	  population	  and	  has	  been	  associated	  with	  lower	  serum	  TG,	  higher	  levels	  of	  HDL-­‐C,	  lower	  levels	  of	  LDL-­‐C,	  and	  lower	  levels	  of	  subclinical	  atherosclerosis	  as	  measured	  by	  coronary	  artery	  calcification.113	  	  In	  our	  population	  level	  data	  we	  found	  that	  the	  APOC3	  R19X	  variant	  is	  much	  rarer	  in	  the	  general	  population	  and	  that	  it	  is	  associated	  with	  increased	  HDL-­‐C	  levels	  (effect=+11mg/dl,	  P=9.9	  x	  10-­‐12)	  and	  decreased	  triglyceride	  levels	  (effect=-­‐65.9mg/dl,	  P=5.8	  x	  10-­‐23)	  (Figure	  6).	  	  The	  majority	  of	  the	  novel	  associations	  occur	  with	  variants	  with	  low	  to	  very	  rare	  frequencies.	  
	  
Figure	  6:	  Triglyceride	  Levels	  in	  R19X	  and	  Adjacent	  Splice	  Mutation	  Carriers	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Gene-­‐level	  Association	  Analysis	  Using	  Exome	  Array	  Genotype	  Data	  As	  the	  majority	  of	  the	  variants	  available	  for	  analysis	  on	  the	  exome	  array	  are	  rare,	  we	  pooled	  the	  missense,	  nonsense,	  and	  splice	  site	  mutations	  in	  each	  gene	  and	  performed	  gene	  burden	  testing.	  	  The	  analysis	  of	  exome	  array	  genotyping	  data	  using	  the	  variable	  threshold	  test	  identified	  10	  genes	  associated	  with	  LDL-­‐C,	  23	  genes	  associated	  with	  HDL-­‐C,	  and	  13	  genes	  associated	  with	  TG.	  	  The	  top	  associations	  were	  between	  LDL-­‐C	  and	  PCSK9	  (P	  =	  4.8	  x	  10-­‐46),	  HDL-­‐C	  and	  CETP	  (2.8	  x	  10-­‐73),	  and	  TG	  and	  APOC3	  (P	  =	  5.3	  x	  10-­‐82)	  (Table	  7).	  	  The	  roles	  of	  all	  of	  these	  genes	  with	  the	  strongest	  associations	  have	  been	  well	  characterized	  in	  lipid	  metabolism.62,97,114	  To	  account	  for	  opposite	  effects	  of	  variants	  within	  a	  gene	  region	  in	  calculating	  the	  burden	  results,	  we	  performed	  the	  SKAT	  test	  using	  nonsense,	  missense,	  and	  splice	  site	  variants	  with	  a	  minor	  allele	  frequency	  lower	  than	  5%.	  	  The	  analysis	  of	  exome	  array	  genotyping	  data	  using	  the	  SKAT	  burden	  test	  identified	  8	  genes	  associated	  with	  LDL-­‐C,	  18	  genes	  associated	  with	  HDL-­‐C,	  and	  7	  genes	  associated	  with	  TG	  after	  accounting	  for	  the	  number	  of	  genes	  tested.	  	  The	  top	  associations	  were	  between	  LDL-­‐C	  and	  PCSK9	  (P	  =	  2.4	  x	  10-­‐94),	  HDL-­‐C	  and	  ANGPTL4	  (6.7	  x	  10-­‐66),	  and	  TG	  and	  ANGPTL4	  (P	  =	  2.1	  x	  10-­‐73)	  (Table	  8).	  	  The	  roles	  of	  all	  of	  these	  genes	  with	  the	  strongest	  associations	  have	  also	  been	  well	  characterized	  in	  lipid	  metabolism.62,115	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Table	  7:	  Top	  Variable	  Threshold	  Gene	  Burden	  Associations	  
Trait	   Gene	   P	  Value	   Effect	  Size	   Variants	  LDL	   PCSK9	   8.6	  x	  10-­‐59	   -­‐0.2	   26	  LDL	   LDLR	   3.1	  x	  10-­‐12	   0.7	   28	  HDL	   CETP	   2.8	  x	  10-­‐73	   -­‐0.2	   15	  HDL	   LPL	   1.2	  x	  10-­‐70	   -­‐0.2	   12	  TG	   APOC3	   5.3	  x	  10-­‐82	   -­‐1.0	   4	  TG	   ANGPTL4	   2.2	  x	  10-­‐47	   -­‐0.2	   11	  Effect	  size	  reported	  in	  standard	  deviation	  units.	  	  Variants	  denote	  number	  of	  single	  variants	  in	  gene	  contributing	  to	  burden	  result.	  	   	  
Table	  8:	  Top	  SKAT	  Gene	  Burden	  Associations	  
Trait	   Gene	   P	  Value	   Effect	  Size	   Variants	  LDL	   PCSK9	   2.4	  x	  10-­‐94	   -­‐0.2	   26	  LDL	   APOE	   3.5	  x	  10-­‐8	   0.1	   4	  HDL	   ANGPTL4	   6.7	  x	  10-­‐66	   0.2	   11	  HDL	   LPL	   5.3	  x	  10-­‐47	   -­‐0.2	   12	  TG	   ANGPTL4	   2.1	  x	  10-­‐73	   -­‐0.2	   11	  TG	   APOC3	   8.1	  x	  10-­‐68	   -­‐1.0	   4	  Effect	  size	  reported	  in	  standard	  deviation	  units.	  	  Variants	  denote	  number	  of	  single	  variants	  in	  gene	  contributing	  to	  burden	  result.	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DISCUSSION	  We	  used	  an	  exome	  array	  to	  genotype	  over	  130,000	  individuals	  at	  almost	  250,000	  sites	  to	  assess	  the	  role	  of	  low-­‐frequency	  and	  rare	  variants	  at	  the	  population	  level.	  	  After	  meta-­‐analyzing	  the	  results	  from	  all	  58	  participating	  studies,	  	  we	  discovered	  several	  new	  genes	  and	  variants	  significantly	  associated	  with	  plasma	  lipid	  levels	  in	  humans.	  	  We	  report	  for	  the	  first	  time	  variants	  in	  the	  genes	  ABCA6,	  
SERPINA1,	  REST,	  FBLN1,	  and	  CCDC117	  associated	  with	  LDL-­‐C	  levels,	  variants	  in	  
TMED6	  and	  CDC25A	  associated	  with	  HDL-­‐C	  levels,	  variants	  in	  PRRC2A,	  COL18A1,	  and	  EDEM3	  associated	  with	  TG	  and	  variants	  in	  MAP1A	  and	  APOC3	  associated	  with	  HDL-­‐C	  and	  TG.	  	  None	  of	  these	  genes	  have	  previously	  been	  associated	  with	  plasma	  lipid	  levels,	  and	  their	  role	  in	  lipid	  metabolism	  remains	  largely	  unknown.	  These	  results	  permit	  several	  conclusions.	  	  First,	  this	  study	  was	  successful	  in	  replicating	  findings	  of	  coding	  mutations	  in	  genes	  with	  well-­‐established	  associations	  with	  plasma	  lipids.	  	  The	  associations	  of	  APOE	  and	  PCSK9	  with	  LDL-­‐C,	  CETP	  and	  LPL	  with	  HDL-­‐C,	  and	  APOA5	  and	  GCKR	  with	  TG	  have	  been	  well	  established	  and	  their	  functions	  well	  characterized.62,97-­‐99	  	  The	  study	  also	  successfully	  replicated	  plasma	  lipid	  associations	  with	  GWAS	  variants	  that	  were	  included	  on	  the	  exome	  array.	  	  This	  establishes	  the	  validity	  of	  the	  genotyping	  as	  well	  as	  the	  analytic	  methods	  employed.	  	  Furthermore,	  conditional	  analysis	  based	  on	  nearby	  loci	  with	  strong	  associations	  was	  successful	  in	  filtering	  out	  numerous	  false	  single	  variant	  signals	  that	  arose	  based	  on	  proximity	  and	  linkage	  to	  associated	  loci.	  Second,	  we	  discovered	  only	  a	  few	  new	  rare	  coding	  variants	  using	  this	  approach.	  	  The	  collective	  sample	  size	  of	  over	  130,000	  individuals	  provides	  sufficient	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power	  to	  detect	  weak	  associations	  of	  low	  frequency	  and	  rare	  alleles	  with	  small	  effect.	  In	  the	  meta-­‐analysis,	  we	  had	  over	  80%	  statistical	  power	  to	  identify	  variants	  with	  an	  effect	  size	  of	  0.2	  standard	  deviations	  down	  to	  0.35%	  frequency	  and	  variants	  with	  an	  effect	  size	  of	  0.4	  standard	  deviations	  down	  to	  a	  0.085%	  frequency	  at	  an	  alpha	  level	  of	  2	  x	  10-­‐7.	  	  Therefore	  we	  can	  reasonably	  conclude	  that	  within	  the	  context	  of	  the	  exome	  array,	  low-­‐frequency	  and	  rare	  coding	  variants	  of	  large	  effect	  in	  the	  frequency	  range	  of	  (0.085-­‐5%)	  do	  not	  contribute	  significantly	  to	  the	  overall	  variation	  in	  plasma	  lipids	  at	  the	  population	  level,	  and	  larger	  sample	  sizes	  will	  be	  needed	  in	  order	  to	  detect	  variants	  with	  smaller	  effects.	  	  Given	  that	  the	  frequency	  of	  recessive	  alleles	  responsible	  for	  Mendelian	  dyslipidemias	  are	  commonly	  much	  lower	  than	  the	  detection	  threshold	  of	  the	  exome	  array,	  it	  is	  not	  surprising	  that	  so	  few	  very	  rare	  variants	  were	  discovered	  in	  this	  analysis.	  Third,	  rare	  and	  low	  frequency	  variants	  collectively	  explain	  only	  a	  small	  fraction	  of	  the	  missing	  heritability	  in	  plasma	  lipid	  levels.	  	  Despite	  the	  relatively	  large	  effect	  sizes	  on	  the	  lipid	  traits	  by	  some	  of	  the	  mutations,	  the	  paucity	  and	  overall	  low	  frequency	  of	  the	  variants	  with	  novel	  associations	  collectively	  only	  explain	  0.002%	  of	  the	  variance	  in	  LDL-­‐C,	  0.003%	  of	  the	  variance	  in	  HDL-­‐C,	  0.006%	  of	  the	  variance	  in	  TG.	  	  However,	  in	  our	  single	  variant	  analysis	  we	  used	  only	  the	  additive	  model	  for	  simplicity.	  	  Factoring	  interactions	  and	  other	  modes	  of	  inheritance	  may	  explain	  a	  collectively	  larger	  fraction	  of	  the	  missing	  heritability.	  	  	   Several	  limitations	  of	  the	  present	  study	  need	  to	  be	  considered.	  	  We	  were	  not	  able	  to	  evaluate	  extremely	  rare	  variants	  that	  may	  be	  unique	  to	  individuals;	  exome	  or	  whole	  genome	  sequencing	  is	  needed	  to	  capture	  this	  type	  of	  variation.	  	  As	  such,	  it	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remains	  possible	  that	  a	  burden	  of	  such	  very	  rare	  mutations	  could	  contribute	  to	  plasma	  lipid	  variation.	  	  If	  so,	  the	  sample	  sizes	  required	  to	  yield	  new	  rare	  variant	  discoveries	  are	  likely	  to	  be	  extraordinarily	  large.	  	  	   The	  Exome	  Array	  is	  constrained	  to	  the	  coding	  and	  splice	  site	  variation	  observed	  in	  the	  ~12,000	  individuals	  who	  comprised	  the	  initial	  exome	  sequencing	  discovery	  set.	  	  Furthermore,	  ~20%	  of	  the	  content	  contributed	  for	  design	  failed	  to	  be	  converted	  into	  genotyping	  assays	  and	  thus,	  these	  variants	  are	  not	  present	  on	  the	  Exome	  Array.	  	  	  Additionally,	  the	  majority	  of	  the	  individuals	  who	  were	  genotyped	  are	  of	  European	  ancestry.	  	  The	  uniformity	  in	  allele	  frequencies	  and	  haplotype	  blocks	  associated	  with	  predominantly	  single	  ancestry	  analysis	  limits	  the	  power	  to	  detect	  true	  associations	  limited	  to	  non-­‐European	  groups.	  	  However,	  our	  group	  also	  conducted	  a	  similar	  exome	  array	  association	  study	  with	  lipids	  and	  myocardial	  infarction	  (MI)	  in	  56,000	  individuals	  of	  African	  and	  European	  ancestry	  and	  identified	  only	  4	  additional	  low	  frequency	  variants	  associated	  with	  HDL-­‐C	  and	  TG	  but	  not	  with	  LDL-­‐C	  or	  MI	  risk.116	  Using	  the	  exome	  array	  to	  genotype	  a	  large	  cohort	  of	  individuals,	  we	  were	  able	  to	  discover	  several	  rare	  variants	  in	  genes	  associated	  with	  plasma	  lipid	  levels.	  	  Looking	  forward,	  it	  will	  be	  important	  to	  further	  investigate	  if	  these	  variants	  are	  associated	  with	  coronary	  heart	  disease.	  	  Very	  little	  is	  known	  about	  the	  function	  of	  the	  newly	  discovered	  genes,	  and	  understanding	  their	  role	  in	  lipid	  metabolism	  may	  provide	  new	  insights	  into	  treating	  patients	  with	  dyslipidemias.	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CONCLUSIONS	  AND	  FUTURE	  DIRECTIONS	  After	  performing	  targeted	  sequencing	  of	  genes	  surrounding	  GWAS	  loci	  in	  participants	  with	  extremely	  high	  or	  low	  HDL-­‐C	  levels,	  we	  did	  not	  discover	  any	  new	  rare	  coding	  variants	  with	  a	  strong	  effect	  on	  HDL-­‐C.	  	  These	  results	  suggest	  that	  rare	  coding	  variants	  may	  not	  be	  significantly	  contributing	  to	  the	  original	  GWAS	  signals	  and	  that	  targeted	  exome	  sequencing	  has	  limited	  utility	  in	  discovering	  functional	  variants	  at	  these	  loci.	  	  Adding	  more	  samples	  to	  the	  study	  will	  better	  power	  the	  analysis,	  but	  this	  is	  unlikely	  to	  translate	  into	  new	  gene	  discoveries.	  	  	  As	  the	  targeted	  sequencing	  data	  are	  unable	  to	  link	  a	  specific	  rare	  coding	  mutation	  to	  nearby	  GWAS	  loci	  in	  most	  cases,	  it	  will	  be	  important	  to	  redirect	  attention	  to	  the	  actual	  GWAS	  SNPs	  that	  were	  initially	  discovered.	  	  Investigating	  the	  role	  of	  possible	  functional	  or	  regulatory	  elements	  at	  these	  sites	  in	  disease-­‐specific	  cell	  lines	  as	  an	  extension	  of	  available	  ENCODE	  data	  may	  be	  fruitful	  in	  identifying	  mechanistic	  schema	  and	  guiding	  future	  experiments.101	  	  Although	  targeted	  sequencing	  has	  had	  some	  success	  in	  suggesting	  coding	  variants	  that	  are	  likely	  contributing	  to	  the	  GWA	  signal	  for	  some	  traits,	  revisiting	  and	  systematically	  studying	  the	  initially	  discovered	  non-­‐coding	  variants	  in	  the	  implicated	  loci	  will	  be	  necessary	  to	  better	  understand	  the	  biologic	  underpinnings	  of	  these	  associations.	  Using	  the	  exome	  array	  to	  genotype	  rare	  variants	  in	  over	  130,000	  individuals,	  we	  have	  discovered	  11	  new	  genes	  associated	  with	  plasma	  lipids.	  	  We	  report	  novel	  associations	  of	  variants	  in	  the	  genes	  ABCA6,	  SERPINA1,	  REST,	  FBLN1,	  and	  CCDC117	  with	  LDL-­‐C	  levels,	  variants	  in	  TMED6	  and	  CDC25A	  with	  HDL-­‐C	  levels,	  variants	  in	  
PRRC2A,	  COL18A1,	  and	  EDEM3	  with	  TG	  and	  variants	  in	  MAP1A	  and	  APOC3	  with	  HDL-­‐
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C	  and	  TG.	  	  We	  also	  reported	  2	  variants	  in	  APOC3	  with	  new,	  strong	  associations	  with	  HDL-­‐C	  and	  TG.	  These	  results	  suggest	  that	  rare	  and	  low	  frequency	  variants	  explain	  a	  small	  portion	  of	  plasma	  lipid	  level	  variance	  at	  the	  population	  level.	  	  The	  generalizability	  of	  these	  conclusions	  with	  regards	  to	  genetic	  architecture	  is	  limited	  by	  the	  content	  of	  the	  exome	  array	  and	  the	  exomes	  from	  which	  the	  array	  SNPs	  were	  gathered;	  however,	  given	  the	  large	  scale	  of	  the	  undertaking,	  these	  results	  suggest	  that	  only	  a	  handful	  of	  other	  rare	  variants	  may	  be	  found	  even	  if	  the	  analysis	  were	  to	  be	  significantly	  extended	  in	  sample	  size	  or	  if	  such	  methodology	  was	  applied	  to	  other	  complex	  traits.	  	   We	  will	  next	  assess	  the	  role	  of	  these	  variants	  with	  CHD.	  	  Our	  group	  is	  also	  leading	  an	  exome	  array	  meta-­‐analysis	  consortium	  investigating	  the	  role	  of	  rare	  and	  low	  frequency	  variants	  in	  causing	  early	  onset	  myocardial	  infarction	  (MI).	  	  We	  will	  intersect	  the	  findings	  from	  the	  lipids	  meta-­‐analysis	  with	  the	  exome	  array	  analysis	  for	  MI	  to	  inquire	  if	  the	  newly	  discovered	  genes	  contribute	  directly	  to	  coronary	  artery	  disease.	  	  Finally,	  very	  little	  is	  known	  about	  the	  genes	  and	  variants	  with	  novel	  associations	  discovered	  using	  the	  exome	  array,	  so	  we	  will	  carry	  out	  functional	  studies	  for	  each	  protein.	  	  Cell-­‐based	  assays	  testing	  for	  the	  LDL	  trait	  are	  in	  progress	  for	  the	  top	  variant	  associations	  with	  plasma	  LDL-­‐C	  levels.	  	  Determination	  of	  the	  function	  these	  discoveries	  in	  lipid	  metabolism	  may	  provide	  new	  insights	  into	  treating	  patients	  with	  dyslipidemias	  and	  coronary	  heart	  disease.	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  in	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  guidance	  from	  GMP,	  DJR,	  and	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  processing	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